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ABSTRACT 
Histone lysine methylation is an important epigenetic mark for regulation 
of gene expression and chromatin organization. Setdb1 (Set domain, bifurcate 1), 
one of the histone lysine methyltransferases, specifically methylates histone H3 
at lysine 9 (H3K9) and participates in transcriptional repression and 
heterochromatin formation. The major task of my thesis work was to investigate 
the epigenetic roles of Setdb1 in regulating brain functions. I started my thesis 
work by examining Setdb1 expression pattern during mouse brain development. 
The most robust signal of Setdb1 was detected in the fetal brains at embryonic 
day 12.5, with a ubiquitous distribution in all the proliferative zones, as well as the 
cortical plate and other regions comprised of postmitotic neurons. The 
expression of Setdb1 decreased as the brain developed, and this down-
regulation profile was correlated to neuronal maturation as examined in a primary 
culture model of mouse cortical neurons. I then generated CK-Setdb1 transgenic 
mice, in which a myc-tagged full length mouse Setdb1 was constantly expressed 
in postmitotic neurons under the control of the CaMK II alpha promoter (CK). The 
expression of mycSetdb1 was detected in NeuN positive cells throughout most 
forebrain regions including cerebral cortex, striatum and hippocampus. A 
sustained increase of Setdb1 in CK-Setdb1 transgenics was verified at both 
mRNA and protein levels. Furthermore, an increase of H3K9 trimethylation was 
detected at major satellite DNA repeats in CK-Setdb1 forebrains, which indicated 
that transgene-expressed mycSetdb1 was functionally active in adult brains.  
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The behavioral phenotype of CK-Setdb1 transgenics was examined by 
using two separate founder lines. Gross neurological functions including body 
weight, locomotion activity, motor coordination, and breeding behavior were 
generally normal in CK-Setdb1 mice. CK-Setdb1 mice were further subjected to 
behavioral paradigms related to mood and cognitive functions. Intriguingly, as 
compared to the littermate controls, CK-Setdb1 mice represent a lower level of 
depression as indicated by decreased total immobility in two different behavioral 
despair tests. Moreover, CK-Setdb1 mice showed an accelerated extinction in 
the learned helplessness paradigm after a delayed interval (7 days), indicating a 
faster recovery from an established status of despair. The potential confounding 
factors, like memory deficits, were ruled out as CK-Setdb1 mice showed normal 
or even improved performances in different memory-related paradigms. Anxiety 
scores and stimulant drug response were normal in CK-Setdb1 mice. Taken 
together, these findings suggested that a specific antidepressant-like phenotype 
was elicited by the over-expression of Setdb1 in adult mice forebrains. 
To further study the molecular mechanism underlying Setdb1-associated 
antidepressant-like behavioral changes, I screened for Setdb1-binding sites in a 
genome-scale by ChIP-on-chip using a tiling microarray from Affymetrix. 
Unexpectedly, Setdb1 showed a very restricted binding profile with a high 
specificity towards ionotropic glutamate receptor genes including the NMDA 
receptor 2B subunit gene Grin2b, which is a new target for the treatment for 
major depression. An increase of H3K9 dimethylation at Setdb1-binding site on 
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Grin2b locus was detected in CK-Setdb1 hippocampus, which was correlated to 
a decrease of Grin2b expression as well as an accelerated desensitization of 
NMDA receptor. Furthermore, Chromosome Conformation Capture (3C) on 
Grin2b locus revealed a repressive chromatin loop structure, which tethered the 
distal Setdb1-binding site (~ 32 Kb downstream of transcriptional start site (TSS)) 
to a proximal intronic region (~12 Kb downstream of TSS) that is enriched for the 
binding of KAP1, a well-studied Setdb1-interacting transcriptional corepressor. 
Taken together, our data indicated that Setdb1 repressed Grin2b expression via 
H3K9 hypermethylation and higher-order chromatin loop formation, which may 
contribute to the antidepressant-like phenotype we observed in CK-Setdb1 mice. 
The second part of my thesis work was to investigate the role of Setdb1 in 
the animal model of a neurodevelopmental disorder - Rett syndrome (RTT). 
Loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 
(MECP2) is the primary cause of RTT. There is an overlap between Setdb1- and 
Mecp2-associated repressive chromatin machineries, which both include histone 
deacetylase complex, H3K9 methyltransferase, DNA methyltransferase and 
heterochromatin protein 1 (HP1). Moreover, in contrast to Setdb1, which is 
downregulated during the cortical neuronal differentiation, Mecp2 is upregulated 
and the expression level is positively correlated to neuronal maturation. 
Therefore, we hypothesized that there is a functional redundancy between 
Setdb1 and Mecp2, and the up-regulation of Setdb1 in mature neurons will 
compensate for brain deficiency due to the loss of Mecp2. To test this hypothesis, 
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I crossed CK-Setdb1 transgenic mice with nestincre-Mecp2 conditional knockout 
mice (Mecp2-/y). The behavior changes of CK-Setdb1/Mecp2-/y mice, including 
body weight, locomotion, motor coordination, and life span, were then compared 
to Mecp2-/y mice. No significant improvements in behaviors or survival were 
observed from CK-Setdb1/Mecp2-/y mice. Because the activation of CK promoter 
is limited to defined population of postmitotic neurons in forebrain, I tested our 
hypothesis by generating another strain of Setdb1 overexpression mice – 
tauSetdb1, in which the expression of mycSetdb1 is under the control of an 
endogenous pan-neuronal active promoter Tau. However, the introduction of 
tauSetdb1 also failed to rescue Mecp2 deficiency. The life span of tauSetdb1/ 
Mecp2-/y was even shorter as compared to Mecp2-/y mice (Kaplan-Meier, p=0.07). 
In conclusion, up-regulation of Setdb1 in adult brain was not sufficient to rescue 
Mecp2 deficiency in the mouse model of RTT. 
One of the most challenges to study neuronal dysfunctions in brain 
diseases is the cellular heterogeneity of central nervous system. Current 
techniques for chromatin studies, including chromatin immunoprecipitation (ChIP) 
assays, usually lack of single cell resolution and are unable to examine the 
neurobiological changes in defined cell populations. In the third part of my thesis 
work, I developed a modified protocol to isolate neuronal nuclei from brain 
homogenates via Fluorescence-Activated Cell Sorting (FACS). In general, total 
nuclei was extracted from frozen brains, neuronal nuclei were then immuno-
tagged with NeuN and sorted via FACS. Besides the NeuN labeling-FACS 
 ix
protocol, I also generated CK-H2BeGFP transgenic mice, in which a histone 
H2B-eGFP (enhanced green fluorescent protein) fusion protein was expressed in 
the nuclei of postmitotic neurons in mouse forebrain. Nuclei extracted from CK-
H2BeGFP brain were directly applied for FACS sorting. By using this protocol, we 
routinely got around 6-8 x106 neuronal nuclei from one adult mouse forebrain, 
which was sufficient for ChIP applications followed by single gene PCR and 
microarray studies. In conclusion, our protocol permits large-scale studies of 
chromatin modifications or any other nuclei events in defined cell populations 
from distinct brain regions. 
Taken together, my dissertation work will lead to a better understanding of 
the epigenetic roles of histone H3K9 methyltransferase Setdb1 in brain functions, 
and may provide new targets for the therapeutic treatment of major depression. 
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CHAPTER I: INTRODUCTION 
Epigenetics - Histone Code 
The term of “epigenetics” refers to heritable changes in gene expression 
and chromosome conformation that do not affect the DNA sequence. There are 
two major areas of epigenetics: i) DNA methylation: the addition of a methyl 
group on cytosine in the context of CpG dinucleotides. Aberrant DNA 
hypermethylation in gene promoter regions is associated with transcriptional 
silencing (Hoffman and Hu, 2006); ii) Histone modifications: covalent 
modifications of core histone tails and ATP-dependent nucleosome remodeling, 
which affect gene transcription by changing chromatin accessibility or serving as 
“docking sites” to further recruit chromatin regulatory factors (Peterson and Laniel, 
2004). Current insight into epigenetics implicates its important roles in both 
normal brain development and the neurobiology of neurobiological diseases, 
which opens the potential of new avenues for treatments (Jiang et al., 2008b). 
Nucleosome is the fundamental unit of chromatin in eukaryotic cells. The 
nucleosome core particle is comprised of approximately 146 bp of DNA wrapped 
around a histone octamer, which is consisted of two copies each of the core 
histones H2A, H2B, H3, and H4. Amino terminal of core histone tails protrude 
from the core nucleosome particle, and are subjected to different 
posttranslational modifications, including acetylation, methylation, 
phosphorylation, ubiquitination and sumolyation (Peterson and Laniel, 2004). 
Characterized by the modification type, position of modified residue, and even 
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the numbers of (methyl) group that is added to the residue, individual histone 
modification reflects distinct chromatin status: transcriptionally active (“open 
chromatin”) or silent (“closed chromatin”). Moreover, multiple histone 
modifications act in combinations to form a “histone code”, which can be 
deciphered by other chromatin regulatory proteins to determine further 
downstream nuclei events (Strahl and Allis, 2000; Jenuwein and Allis, 2001).  
Acetylation of histone lysine residues removes positive charges from 
histone proteins, thus decreases the histone-DNA binding affinity and increases 
chromatin accessibility. Histone acetylation is primarily associated with open 
chromatin and gene activation (Berger, 2007). The steady-state level of histone 
acetylation is dynamically balanced by two groups of enzymes with opposite 
activities: histone acetyltransferase (HAT) and histone deacetylase (HDAC). A 
class of chemical compounds called HDAC inhibitors (HDACi) can interfere with 
HDAC activity and increase the overall level of histone acetylation in vivo. HDACi 
are widely studied in cancer research and considered as a new class of 
anticancer reagents, since they show highly selective effects in tumor cells by 
inhibiting proliferation and inducing apoptosis (Hadnagy et. al., 2008). Also, as 
will be discussed in detail later, HDACi show striking effects on brain functions 
and are implicated in the treatment of neurological disorders.  
Histone methylation is another modification on histone tails by the addition 
of one, two, or three methyl groups to certain lysine or arginine residues. By 
recruiting different types of chromatin proteins, histone methylation can regulate 
 3
chromatin status in both directions. For example, histone lysine methylation at 
H3K4, H3K36 and H3K79 is generally associated with active chromatin; while 
methylation at H3K9, H3K27 and H4K20 is associated with repressive chromatin 
(Volkel and Angrand, 2007). Histone lysine methylation is catalyzed by a group of 
enzymes called histone lysine methyltransferases (HMTs) (Rea et al., 2000). 
Most of the HMTs contain an evolutionarily highly conserved (in fungi, plant, 
Drosophila, and mammalians, but not bacteria) SET domain along with two 
flanking cysteine-rich sequences, the PRE-SET and POST-SET domains, which 
are required for the methyltransferase activity (Volkel and Angrand, 2007). The 
SET domain is named after three Drosophila chromatin regulating proteins: 
Su(var)3–9, Enhancer of zeste (E(z)), and Trithorax. Different from acetylation, 
histone methylation has been long considered as a stable and irreversible 
modification since the half-life for methylation is almost the same as the protein 
itself (Bui et al., 2007). However, this has been disproved by the recent discovery 
of two families of histone demethylases (Klose and Zhang, 2007): the Lysine 
Specific Demethylase 1 (LSD1) and Jumonji domain-containing histone 
demethylases (JmjC). Still, as a relatively stable chromatin mark, histone 
methylation is thought to be involved in the regulation of “transcription memory” 
and to provide long-lasting effects on chromatin organization during the 
development of both normal and diseased brains. 
Setdb1/ESET - a Histone H3K9 specific methyltransferase  
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So far, there are five different HMTs that catalyze H3K9 methylation 
identified in mammalian cells: Suv39-h1, Suv39-h2, G9a, Eu-HMTase 1 (also 
known as G9a-like protein, GLP) and Setdb1 (also known as ESET). Although 
Suv39-h1 and Suv39-h2 catalyze H3K9 methylation at all three levels (mono, di 
and tri) in vitro, they seem to be specifically responsible for the establishment of 
H3K9 tri-methylation in pericentric heterochromatin regions in vivo (Aagaard et 
al., 1999; Melcher et al., 2000). Unlike Suv39h1/2, G9a and Eu-HMTase 1 
catalyze mono- and di-methylation of H3K9 in vivo, and are involved in the 
regulation of euchromatic gene expression in mammalian cells (Tachibana et al., 
2001; Rice et al., 2003; Stewart et al., 2005).  
SETDB1 was first identified by Harte et. al. in 1999 as a human gene 
located on chromosome 1q21 (Harte et al., 1999). Two years later, its encoding 
protein was further studied by Schultz and his colleagues and described as a 
H3K9 specific HMT involved in euchromatic gene repression by associating with 
a transcriptional corepressor KAP-1 (Schultz et al., 2002). In the same year, 
mouse Setdb1 (92% homolog to human SETDB1) was also identified as an 
interacting partner of a transcription factor, ERG, thus named as ESET (ERG-
associating protein with SET domain) (Yang et al., 2002). Mouse Setdb1 is a 
single copy gene mapped to mouse chromosome 3, which contains 22 exons 
encoding a 4.6 KB full length transcript and an alternative splicing variant of 2.6 
KB C-terminal truncated form (Blackburn et al., 2003). Both human and mouse 
Setdb1 proteins contain a Tudor domain, a methyl-CpG binding domain (MBD), 
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and the highly conserved PRE-SET, SET, and POST-SET domains. Different 
from other H3K9 HMTs, the SET domain of Setdb1 is split by a large piece of 
insertion; however, it still possesses the intrinsic HMT activity with a high 
specificity towards H3K9. Setdb1 was shown to catalyze all three levels of H3K9 
methylation both in vitro and in vivo, and in vivo its enzyme activity towards 
H3K9me2 (the conversion of di- to tri-methyl state at H3K9) was highly enhanced 
by collaborating with a murine activating transcription factor 7-associated factor 
(Atf7ip, also known as AM, Mcaf1) (Wang et al., 2003). The ability of Setdb1 to 
methylate H3K9 was also influenced by other preexisting histone modification, 
including global acetylation, phosphorylation on lysine 14, and any modifications 
on lysine 9 (Schultz et al., 2002). Setdb1-associated HMT activity is essential for 
mouse early development, as evidenced by the peri-implantation lethality of 
homozygous Setdb1-mutant mice, in which exons 15 to 22 encoding those 
enzyme activity essential domains were replaced by a beta-geo cassette (Dodge 
et al., 2004). Also, studies on the same animals by checking the expression 
pattern of lacZ report gene, which was under the control of endogenous Setdb1 
promoter, revealed an ubiquitous expression pattern through the entire mouse 
embryo (Dodge et al., 2004). 
dSetdb1 (also known as dEset or egg), the Drosophila homolog to mouse 
Setdb1, was identified in 2006, which encodes a protein also containing a split 
SET domain, as well as Tudor, MBD, and HDAC interacting domains (Stabell et 
al., 2006). The full length of dSetdb1 transcript was detected throughout 
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Drosophila embryo development including the central nervous system. Studies 
on mutant flies with reduced level or genetic ablation of dEset indicated that the 
essential role of dEset in multiple stages of development and survival (Stabell et 
al., 2006; Seum et al., 2007). Moreover, dSetdb1-overexpressing fly showed 
polytene chromosome and chromocenter defects and died during early 
developmental stage (Seum et al., 2007), which indicated that not only the 
presence, but also the correct dosage of dSetdb1 is critical for fly development. 
Different from mammalian Setdb1 that is mainly located in euchromatic 
chromatin, dSetdb1 was detected in both euchromatic and heterochromatic 
regions, including chromocenter and the small chromosome 4. Moreover, as a 
histone H3K9 HMT in Drosophila, dSetdb1 showed high specificity towards the 
chromosome 4, since the H3K9 methylation signal and HP1 deposition was 
mainly lost from polytene chromosome 4 in salivary gland from dSetdb1-null 
larvae (Seum et al., 2007; Tzeng et al., 2007). Interestingly, when checked in 
Su(var)3-9 null fly, both H3K9 methylation and HP1 signal was strongly reduced 
in the chromocenter, but remained unchanged in the chromosome 4 (Stabell et 
al., 2006). Moreover, most recent studies reported that dSetdb1 was essential for 
the establishment of H3K9 tri-methylation in pericentric heterochromatin regions 
in germline-stem cell (GSCs), while such function was taken over by Su(var)3-9 
later as GSCs differentiated into egg chambers (Clough et al., 2007; Yoon et al., 
2008). Taken together, it indicates that although targeting the same histone 
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lysine residue - H3K9 - in Drosophila, dSetdb1 and Su(var)3-9 function in a 
different spatial and temporal manner during fly development.  
H3K9 methylation is well established as an epigenetic mark of silent 
chromatin involved in transcriptional repression and constitutive heterochromatin 
formation; although such repressive roles were challenged by recent findings that 
H3K9 methylation was also present in transcribed region of active genes and 
associated with transcriptional elongation (Vakoc et al., 2005). As a H3K9-
specific HMT, accumulating evidence indicates that Setdb1 participates in 
transcriptional repression in facultative heterochromatin regions by interacting 
with various of chromatin regulatory protein and protein complex: i) Erg, a 
transcription factor encoded by a Ets-related oncogene, which is critically 
involved in neoplastic transformation (Yang et al., 2002). ii) KRAB domain-
associated protein 1 (KAP1, also known as TIF1β, Trim28). KAP1 directly 
interacts with the KRAB-domain-containing zinc-finger (KRAB-zfp) superfamily of 
transcription repressors, and recruits histone deacetylase complex NuRD, HP1, 
as well as Setdb1. Along with all the associating proteins, KAP1 facilitates the 
formation of a microenvironment of heterochromatin at euchromatic sites, which 
contributes to the gene silencing and position-effect variegation in mammalian 
cells (Ayyanathan et al., 2003; Sripathy et al., 2006). Depletion of Setdb1 or HP1 
proteins attenuated KAP1/KRAB-zfp mediated transcriptional repression 
(Sripathy et al., 2006). iii) mSin3/HDAC1-2 corepressor complex: Setdb1 
interacts with mSin3 via its N-terminal Tudor domain (Yang et al., 2003). The 
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truncated form of Setdb1 that is lack of the MBD and SET domains enhanced its 
binding to mSin3, which indicated that Setdb1-mediated transcriptional 
repression is not solely dependent on its HMT activity (Yang et al., 2003). iv) 
methyl-CpG binding protein 1 (MBD1): Setdb1 formed a stable complex with 
MBD1 and repressed MBD1-targeted gene transcription, like p53BP2 (Sarraf and 
Stancheva, 2004). Such complex was also recruited by the large subunit ( p150) 
of the chromatin assemble factor CAF-1 and contributed to the maintenance of 
H3K9 methylation at S phase in a DNA replication-dependent manner (Sarraf 
and Stancheva, 2004). Interestingly, the p150 subunit of CAF-1 also directly 
associated with HP1 proteins at late S phase to support the formation of 
heterochromatin (Eissenberg and Elgin, 2000). Moreover, v) The Setdb1-
interacting factor Atf7ip (mAM), also known as MBD1-containing chromatin-
associated factor (MCAF), bound directly to the transactional repression domain 
(TRD) of MBD1 and facilitated its transcriptional repression function (Fujita et al., 
2003; Ichimura et al., 2005). vi) Setdb1 directly interacted with the de novo DNA 
methyltransferases DNMT3A, and repressed the expression of p53BP2 and 
RASSF1A in vivo by mediating H3K9 methylation in the CpG methylated 
promoters (Li et al., 2006a). Taken together, it implies that Setdb1 may co-exist 
with all the interacting partners to form one huge chromatin-regulatory complex; 
or most likely it may participate in different machinery to target different genomic 
loci, or to function at different developmental stages or in different cell types. 
Implications of histone acetylation in brain functions 
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As mentioned above, histone acetylation is primarily associated with open 
chromatin formation and transcriptional activation. In recent years, the critical role 
of histone acetylation in brain functions has been illuminated by the studies of a 
group of chemical reagents named HDAC inhibitors (HDACi). HDACi interfere 
with the removal of acetyl group from histones, and therefore elevate the overall 
level of histone acetylation. Improved cognitive functions have been observed 
after the administrations of different HDACi. Moreover, HDACi are shown to 
ameliorate behavioral deficits in animal models of neurodegenerative diseases 
and psychiatric disorders, which opens a new avenue for potential therapy of 
brain diseases (Abel and Zukin, 2008).  
It has been reported that HDACi enhanced synaptic plasticity and 
improved learning and memory (Levenson and Sweatt, 2005; Putignano et al., 
2007). Elevated histone acetylation was associated with enhanced long-term 
potential in hippocampal CA1 synapse and contributed to the formation and 
consideration of long-term memory in the contexture fear conditioning paradigm 
(Levenson et al., 2004; Chwang et al., 2006). The underlying mechanisms may 
include the activation of ERK-MAPK pathway after the activation of NMDA 
receptor; and CBP-CREB dependent transcriptional activation on genes involved 
in long-term memory, including the brain-derived neurotrophin factor Bdnf gene 
(Levenson et al., 2004; Chwang et al., 2006; Bredy et al., 2007; Vecsey et al., 
2007). Epigenetic programming by environmental enrichment, which also 
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increases histone acetylation level, was shown to re-establish long-term learning 
and memory in an animal model of neuronal atrophy (Fischer et al., 2007). 
Huntington’s disease (HD) is an inherited progressive disorder caused by 
an abnormal expansion of a polymorphic stretch of CAG in a faulty gene Htt, 
which triggers the gradual destruction of neurons in brain. Early studies reported 
that HDACi reversed neurodegeneration progress and extended life span in a 
Drosophila model of polyglutamine disease (Steffan et al., 2001). The putative 
therapeutic effects of HDACi, including sodium butyrate, suberoylanilide 
hydroxamic acid (SAHA) and phenylbutyrate, were further reported from the 
studies on two different transgenic mouse models of HD (Ferrante et al., 2003; 
Hockly et al., 2003; Gardian et al., 2005). Notably, the safety of sodium 
phenylbutyrate was evaluated in clinic trials and appeared to be a well-tolerated 
medicine in human HD patients (Hogarth et al., 2007). Parkinson's disease (PD) 
is another prevalent neurodegenerative disease characterized by impaired motor 
functions. Mutations in a neuronal protein, α-synuclein, were identified in family 
PD patients. Studies in Drosophila indicated that α-synuclein mediated neuronal 
death by inhibiting HAT protein activity and decreasing histone acetylation; 
moreover, such neurotoxicity was reversed by administration of HDACi 
(Kontopoulos et al., 2006).  
Rubinstein-Taybi syndrome (RTS) is a malformation syndrome 
characterized by distinctive facial features and mental retardation. Mutations in 
CREB binding protein CBP are identified in RTS patients, and the CBP+/- mutant 
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mice are capable of replicating the cognitive deficits in RTS. CBP is known as a 
transcriptional cofactor that contains HAT activity. The HDACi, SAHA and 
trichostatin A (TSA), were shown to compensate for the loss of histone 
acetylation in CBP+/- mice and ameliorate cognitive deficits (Alarcon et al., 2004; 
Korzus et al., 2004).  
Both DNA methylation and histone modifications are implicated in gene 
dysfunctions in Schizophrenia. The down-regulation of Reelin expression has 
been found in brains from patients with schizophrenia and bipolar disorder with 
psychosis. Condensed CpG sites for potential DNA methylation were identified in 
Reelin promoter region, and HDACi were shown to accelerate the removal of 
DNA methylation and increase Reelin expression in heterozygous reeler mutant 
mice (Costa et al., 2002). Recent studies in our lab checked the roles of histone 
methylation in regulating a GABAergic transcript GAD1, which is also down-
regulated in schizophrenia brains. We found that at the GAD1 promoter, a 
decrease of an “open” histone methylation mark, the trimethylation of H3K4 
(H3K4me3), was correlated with the decrease of GAD1 expression in prefrontal 
cortex from diagnosed schizophrenia patients (Huang and Akbarian, 2007; 
Huang et al., 2007). Furthermore, the atypical antipsychotic, clozapine, was 
shown to increase the levels of H3K4me3 and a GABAergic histone 
methyltransferase, mixed-lineage leukemia 1 (Mll1), in mouse cerebral cortex 
(Huang et al., 2007).  
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Epigenetic mechanisms are highly involved in the development and 
treatment of mood disorders. Early life experience including maternal care shows 
effects on adult behavior response to stress. Dr. Weaver and his colleagues 
reported that maternal licking and grooming influenced hypothalamic-pituitary-
adrenal (HPA) axis functions and anxiety-related behaviors in rodent offspring, 
via epigenetic reprogramming in the glucocorticoid receptor (GR) gene promoter 
(Weaver et al., 2004a; Weaver et al., 2006). Notably, such alterations established 
during early brain development were reversed by the administration of HDACi 
trichostatin A (TSA) in adult rodents, which provided strong evidence of the 
potential therapeutic effects of HDACi on anxiety disorders in adulthood. Histone 
modifications were also studied in the animal model of major depression (MD). 
Chronic administration of a classic antidepressant imipramine was shown to 
increase histone acetylation at a neuron specific promoter of Bdnf, and reverse 
the decrease of Bdnf expression in a chronic stress depression mice model 
(Tsankova et al., 2006). Such effects were partially mediated by the 
downregulation of HDAC5, since increase of HDAC5 in hippocampus abolished 
the antidepressant effects of imipramine (Tsankova et al., 2006). More direct 
evidence on HDACi-mediated antidepressant-like actions came from recent 
studies in our lab. Our data showed that HDACi sodium butyrate alone, or 
synergistically with a SSRI antidepressant fluoxetine, reduced the level of 
behavioral despair, as indicated by a decrease of total immobility in tail 
suspension test (Schroeder et al., 2007).  
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Glutamate receptor genes are new candidates for major depression 
Major depression (MD) is a recurrent and disabling neuropsychiatric 
disorder affect 7% of the population world wide. Although recognized by mankind 
hundreds of years ago, the etiology of MD is still a puzzle. Even now, the 
diagnosis of MD is still based on symptoms, including the pervasive low mood, 
low self-esteem, feelings of helplessness and guilt, loss of interest of previously 
enjoyed activities, and changes in appetite and sleep. In contrast to the limited 
understanding of the etiology of MD, there are certain effective treatments 
available, include antidepressant medications, electroconvulsive seizures, and 
behavioral psychotherapy. Current antidepressants are from three major classes: 
i) tricyclic antidepressants: imipramine. ii) selective serotonin/norepinephrine 
reuptake inhibitors (SSRIs, SNRIs): fluoxetine; and iii) monoamine oxidase 
inhibitors (MOIs): tranylcypromine. All these antidepressant drugs are developed 
based on the hypothesis that MD is due to a deficiency of central monoamine 
system, which can be reversed by interring with either the monoamine reuptake 
or metabolism. Although effective, current antidepressants only help on around 
60% of MD patients with 30% remission; and usually it takes several weeks or 
month for them to take action. There is a discrepancy between the acute effects 
of current antidepressants on the monoamine levels in CNS and the delayed 
onset of their clinic actions, which suggest that although initiated by the activation 
of monoamine pathway, the long-term effects of antidepressants are mediated by 
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some other cell events, which are either downstream or unrelated to the 
monoamine system.  
Converging lines of evidence have suggested that excitatory glutamate 
neurotransmission is involved in the neuropathophysiology of MD and the 
mechanism underlying the action of antidepressants. Altered levels of glutamate 
and glutamate receptors have been reported in the brains from MD patients and 
suicide victims (Nowak et al., 1995; Meador-Woodruff et al., 2001; Pfleiderer et 
al., 2003), as well as in rodent brains regions after exposure to stress, which is 
considered as a major risk factor of depression (Bartanusz et al., 1995; 
Fitzgerald et al., 1996; Singewald et al., 1996; Wieronska et al., 2001). In 
addition, chronic administrations of classic antidepressants influenced both the 
activity and expression levels of the major classes of glutamate receptors in brain 
regions involved in the control of mood (Bleakman et al., 2007; Pittenger et al., 
2007; Pilc et al., 2008).  
Glutamate receptors may serve as new targets for the discovery of small 
molecule modulators with therapeutic properties in MD. Studies have been 
focused on the ionotropic NMDA receptors. Reduction of both depression- and 
anxiety-related behaviors was reported in the mouse model with genetic ablation 
of the NMDA receptor 2A subunit (Boyce-Rustay and Holmes, 2006). Moreover, 
convincing antidepressant-like effects of NMDA receptor antagonists including 
ketamine, MK-801, and Ro5-6981 (NR2B/Grin2b selective antagonist), were 
reported in various behavior despair paradigms, which are preclinical animal 
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models used for antidepressants efficiency evaluation (Garcia et al., 2008; 
Maeng et al., 2008). NMDA receptor antagonists were also tested in clinical trials 
of MD patients. Berman and his colleagues reported that one single infusion of 
ketamine in MD patients resulted in an average reduction of around 15 points in 
Hamilton Depression Rating Scores. Such robust effect was rapid (within 4 hrs) 
and lasted up to two weeks after infusion (Berman et al., 2000). The 
antidepressant effect of ketamine was further verified by Zarate et al on patients 
with treatment-resistant MD (Zarate et al., 2004). Most recently, clinical studies 
on a selective NMDA receptor NR2B subunit antagonist, CP-101,606, also 
showed a robust and relative sustained antidepressant effect, along with a good 
safety and tolerability, in treatment-refractory MD patients (Preskorn et al., 2008).  
Ionotropic AMPA receptors seem to exert effects opposite to NMDA 
receptors in the treatment of MD. Mice with genetic ablation of a main AMPA 
receptor subunit GluR-A represent a depression-like behavioral phenotype along 
with the neurochemical changes including increased levels of glutamate and 
NMDA receptor subunit NR-1 (Chourbaji et al., 2008). Elevation of AMPA 
receptor signal by AMPA receptor potentiators (ARPs), LY404187 and its active 
isomer LY451646, up-regulated Bdnf expression and enhanced progenitor cell 
proliferation in the hippocampal formation of rodent brains (Mackowiak et al., 
2002; Bai et al., 2003), which are the two potential mechanisms underlying 
antidepressant treatments. In addition, administrations of classic antidepressants 
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(tianeptine and fluoxetine) potentiated AMPA receptor activity by increasing the 
phosphorylation of GluR1 (Svenningsson et al., 2007).  
Antidepressant potentials are also related to the metabotropic glutamate 
(mGlu) receptors. Based on the homology and functional biology, mGlu receptors 
are divided in 8 subtypes and 3 groups: Group I (mGlu 1 and 5), Group II (mGlu 
2 and 3), and Group III (mGlu 4, and 6-8). The activation of group I mGlu 
receptors enhance glutamate excitatory actions, while group II and III negatively 
modulate glutamate efflux and neuronal excitability. Antidepressant-like effects 
were reported in animal studies after administrations of group I (mGlu1, 5) and 
group II (mGlu2/3) mGlu receptor antagonists, as well as group III (mGlu7, 8) 
mGlu receptor agonists (Pilc et al., 2008). Antidepressant-like behavioral 
phenotypes were reported in genetic engineering mice with the lack of mGlu5 
(group I) and mGlu2 (group II) expression (Morishima et al., 2005; Li et al., 
2006b). Interestingly, mGlu7 (group III) deficient mice also exhibited 
antidepressant-like and anxielytic activities, which are contrary to the evidence 
from pharmacology studies (Cryan et al., 2003; Palucha et al., 2007). 
Loss of MECP2 functions is the primary cause of Rett syndrome 
Rett syndrome (RTT) is a neurodevelopmental disorder affecting almost 
exclusively females, which indicates an X-linked dominant inheritance with 
lethality in hemizygous males. RTT patients usually develop normally until 6-18 
months after birth, followed by a rapid regression including the loss of acquired 
speech and motor skills, mental retardation, intermittent hyperventilation, and 
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autonomic disturbances. Although RTT patients show severe deficiency in brain 
functions, neuropathological studies of RTT brains failed to reveal evidence of 
neurodegeneration, or any other obvious abnormality except a reduction in brain 
weight and size, which was due to a decrease in neuronal soma size and an 
increase in cell packing density (Johnston et al., 2003). In 1999, genetic studies 
of RTT mapped to a gene on human Xq28 that encodes the methyl-CpG binding 
protein 2 (MECP2) (Amir et al., 1999). Mutations in MECP2 are thought to be the 
main cause of RTT, since they have been identified in around 80% of RTT 
patients. Most of the mutations are clustered within two functional domains of 
MECP2, the methyl-CpG binding domain (MBD) and the transcriptional 
repression domain (TRD), which cause partial or complete loss of MECP2 
functions (Christodoulou and Weaving, 2003). In 2001, two groups generated 
Mecp2-knockout mice and reported that Mecp2-null mice developed RTT-like 
neurological and behavioral changes including the reduction in nerve cell size 
and body weight, hypoactivity and premature death (Chen et al., 2001; Guy et al., 
2001). Mecp2 is highly expressed in mammalian brains, and its activation during 
brain development is correlated with neuronal maturation (Akbarian et al., 2001; 
Shahbazian et al., 2002b). The phenotype of conditional knockout mice with 
brain-specific loss of Mecp2 was indistinguishable from that of Mecp2-null mice. 
Furthermore, mice with specific loss of Mecp2 in postmitotic neurons developed 
a similar, but less severe phenotype in late life (Chen et al., 2001). Taken 
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together, these studies indicate that the neurologic symptoms of RTT are mainly 
due to MECP2 deficiency of mature neurons in the central nervous system.  
Mecp2 functions in transcriptional regulation by bringing two major 
epigenetic mechanisms together - DNA methylation and histone modifications. 
Mecp2 binds to methylated DNA and recruits chromatin modifying proteins, 
including mSin3a/HDAC1/2 corepressor complex (Nan et al., 1998), H3K9 
specific HMT Suv39h1 (Lunyak et al., 2002; Fuks et al., 2003), heterochromatin 
protein HP1 (Agarwal et al., 2007), and chromatin remodeling complex SWI/SNF 
(Harikrishnan et al., 2005). Mecp2 is also associated with the maintenance DNA 
methyltransferase 1 (Dnmt 1) (Kimura and Shiota, 2003). Although no obvious 
changes of the transcription profile were observed in the whole brains from 
Mecp2-null mice (Tudor et al., 2002), Mecp2-mediated repression was detected 
in defined gene regulatory regions, for example, the neural activity-dependent 
neurotrophin gene Bdnf (Chen et al., 2003; Martinowich et al., 2003), the 
imprinted gene distal-less homeobox 5 (Dlx5) (Horike et al., 2005), and genes 
involved in cancer development, like multiple drug resistant gene 1 (Mdr1) (El-
Osta et al., 2002). Most recently, both the transcriptional repression and 
activation were reported from the cDNA microarray analysis on the specific brain 
region hypothalamus from mice with the disruption of Mecp2 expression, and the 
transcriptional activator CREB was shown to be involved in Mecp2-mediated 
activation (Chahrour et al., 2008). Besides regulating euchromatic gene 
expression, Mecp2 also participates in higher-order heterochromatin organization. 
 19
Mecp2 was concentrated in DAPI-enriched heterochromatin regions of mature 
neurons (Lewis et al., 1992; Shahbazian et al., 2002b), and promoted chromatin 
compaction and nucleosome clustering via directly interaction with both 
methylated and un-methylated DNA, as well as the linker histone protein H1 
(Georgel et al., 2003; Nikitina et al., 2007; Ishibashi et al., 2008). 
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Goals and rationale 
Epigenetic mechanisms play critical roles in brain functions and contribute 
to both the development and treatment of neurological disorders. Striking findings 
have been reported from the studies of the active chromatin mark histone 
acetylation, and a potential link was established between the elevation of overall 
histone acetylation level and improved brain functions. My thesis work was to 
study this model further by investigating the epigenetic role of a silent chromatin 
mark - H3K9 methylation - in adult mouse brain, by using a transgenic animal 
model with the over-expression of a H3K9 specific histone methyltransferase 
Setdb1 in postmitotic neurons. Our studies will extend the current knowledge 
about epigenetic regulation in brain functions, and provide potential new targets 
for therapeutic treatments in psychiatry disorders. 
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CHAPTER II: SETDB1 HISTONE METHYLTRANSFERASE ELICITS 
ANTIDEPRESSIVE PHENOTYPES AND REGULATES HIGHER ORDER 
CHROMATIN AT THE NMDA RECEPTOR GENE GRIN2B. 
This work was conducted under the direction of Dr. Schahram Akbarian. My 
contribution in this work was to execute the majority of the experiments including 
the generation of transgenic mice, most of the behavioral assays, microarray 
assay, chromatin immunoprecipitation, Western blot, immunostainings and RT-
PCR. Frederick Schroeder contributed by conducting depression-related 
behavioral studies. Rahul Bharadwaj contributed by conducting chromosomal 
conformation capture experiments. Gilles Martin contributed by conducting whole 
cell recordings. Juerg Straubhaar contributed by conducting microarray data 
analysis. Evgeny Rogaev contributed by conducting bioinformatic analysis of 
KRAB regulatory elements. Yin Guo contributed by conducting 
Immunohistochemistry and animal tagging and genotyping. Anouch Matevossian 
contributed by assisting chromatin immunoprecipitation and PCR assay. The 
manuscript was primarily prepared by Dr. Akbarian, while I contributed to the 
Materials and Methods, Figures and Legends. 
Abstract 
Altered regulation of histone acetylation profoundly affects depression-related 
behaviors in the preclinical model, but the therapeutic potential of other types of 
epigenetic modifications, including histone (lysine) methylation, remains 
unexplored. Here, we report that mice with increased expression and activity of 
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the histone H3K9-selective methyltransferase Setdb1 in adult forebrain neurons 
show antidepressant-like phenotypes, in the context of normal or improved 
learning and memory. Genomic occupancy by Setdb1 overall was extremely 
limited, but included multiple ionotropic glutamate receptor genes. Chromosome 
conformation capture at the Grin2b locus, encoding NMDA receptor subunit 
NR2B, revealed a single loop formation tethering the Setdb1-target sequence to 
a site highly enriched with the transcriptional corepressor, KAP1.  Setdb1-
regulated H3K9 methylation at Grin2b was associated with decreased NR2B 
subunit expression and accelerated desensitization of NMDA receptors in 
prefrontal cortex and hippocampus. Therefore, Setdb1 histone methyltransferase 
and higher order chromatin structures at NMDA receptor genes provide novel 
targets for antidepressant treatments. 
Introduction 
Depression, one of the prime causes for illness-related disability in the United 
States and world wide, carries significant suffering and economic burden. 
Conventional antidepressants primarily interfere with monoamine signaling but 
remain ineffective in more than 40 % of affected individuals, therefore stressing 
the need to explore novel treatment strategies in clinical settings and preclinical 
models (Berton and Nestler, 2006). Recent findings highlight a potential link 
between epigenetic regulation of gene expression and neuronal and behavioral 
plasticity (Alarcon et al., 2004; Alter and Hen, 2008; Borrelli et al., 2008; Fischer 
et al., 2007; Jakobsson et al., 2008; Korzus et al., 2004; Lubin et al., 2008; Miller 
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and Sweatt, 2007; Nelson et al., 2008; Weaver et al., 2004; Wood et al., 2006). 
In particular, interference with the mechanisms regulating histone acetylation 
affects the animal’s response in behavioral paradigms related to depression and 
resilience to stress (Tsankova et al., 2006; Renthal et al., 2007; Schroeder et al., 
2007; Borrelli et al., 2008). However, the therapeutic potential of chromatin 
modifiers regulating the numerous types of histone modifications other than 
lysine acetylation (e.g., site-specific lysine and arginine methylation, sumolyation, 
ubiquitinylation, serine phosporylation, proline isomerization) (Berger, 2007)  
remains largely unexplored.  Here, we report antidepressive phenotypes in 
transgenic mice expressing in adult forebrain high levels of Set domain bifurcated 
1 (Setdb1, or ERG-associated protein with SET domain, Eset) (Schultz et al., 
2002; Yang et al., 2002), a histone H3-lysine 9 specific methyltransferase which 
normally is downregulated after development. Setdb1 occupancy in the genome, 
while overall extremely limited, was found at multiple glutamate receptor genes 
including Grin2b (encoding the NMDA receptor subunit NR2B), where it was 
associated with repressive chromatin remodeling at a chromosomal loop 
formation. Intriguingly, GRIN2B is strongly associated with genetic risk for bipolar 
affective disorder in selected populations(Fallin et al., 2005; Avramopoulos et al., 
2007) and furthermore, the nonselective N-methyl-D-aspartate (NMDA) 
antagonist, ketamine, and the NR2B-selective antagonist, CP-101,606 were 
recently identified as fast-acting antidepressants in subjects with treatment-
resistant depression (Berman et al., 2000; Zarate et al., 2006; Preskorn et al., 
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2008). Therefore, Setdb1 histone methyltransferase, regulating chromatin at sites 
of glutamate receptor genes, emerges as a novel target for antidepressive 
interventions. 
Results 
Neuronal H3K9 methyltransferase activity is up-regulated in CK-Setdb1 
forebrain. 
Immunoblotting, qRT-PCR and in situ hybridization studies revealed robust 
Setdb1 expression throughout the prenatal brain, but low to moderate levels in 
the adult wildtype (Fig. 1-1a,b and data not shown). To maintain high levels of 
expression in adult forebrain neurons, we generated transgenic mice expressing 
a myc epitope-tagged murine Setdb1 cDNA (Yang et al., 2003) under control of 
the CamIIKa (CK) promoter. Two transgenic lines from different founders showed 
neuronal expression, with nuclear localization, in cortical layers II-VI, 
hippocampus, striatum and additional forebrain structures (Fig. 1-1c,d and 
Supplementary Fig. 1-1).  
The H3-lysine 9 specific methyltransferase, Setdb1, is thought to regulate mono-, 
di- and trimethylated H3K9 in constitutive (including pericentric) heterochromatin 
(Lee et al., 2008; Yoon et al., 2008) and facultative heterochromatin (Schultz et 
al., 2002). To test whether the 2- to 5-fold increase in full length 180 kD Setdb1 in 
forebrain of adult CK-Setdb1 mice (Fig. 1-1e,f) resulted in altered H3K9 
methylation, we immunoprecipitated chromatin extracts (ChIP) with anti-trimethyl 
H3K9 (H3K9me3) antibody and then probed the ChIP DNA - without prior PCR 
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amplification - with a major satellite sequence to label pericentric repeats. Murine 
pericentric heterochromatin is mainly comprised of A/T rich major satellite 
repeats comprised of approximately 105 copies of a 234 bp unit (Waterston et al., 
2002), with levels of H3K9me3 already high at baseline (Martens et al., 2005). 
Still, pericentric H3K9me3 in CK-Setdb1 forebrain was increased by more than 
50% (Fig. 1-1g); thereby suggesting that H3K9 methyltransferase activity is up-
regulated in the transgenic animals.  
CK-Setdb1 mice exhibit an antidepressive phenotype  
General neurological functions remained unaltered in CK-Setdb1 mice, except for 
a small change in rotarod performance (Supplementary Fig. 1-2). However, 
widespread expression of Setdb1 transgene in adult forebrain, including 
prefrontal cortex, hippocampus and other portions of cortico-limbic circuitry (Fig. 
1-1c and Supplementary Fig. 1-1) could affect emotional and depression-
related behaviors. To examine this, the Porsolt forced swim test (FST) was 
applied to transgenic line #1 (see above) and the tail suspension test (TST) to 
line #2. These tests, classical behavioral despair paradigms sensitive to acute 
and chronic antidepressant treatment (Porsolt et al., 1978; Dulawa et al., 2004; 
Cryan and Holmes, 2005), measure the time spent immobile during a six-minute 
test interval with the animal placed in a water tank or suspended by the tail. CK-
Setdb1 mice, in comparison to wildtype littermates, showed a significant 20-30% 
reduction in despair-related immobility for both TST and FST (Fig. 1-2a,b). Such 
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decrease in immobility is expected based on studies in outbred mice treated with 
standard SSRI (Crowley et al., 2006).  
To further explore the antidepressive phenotype in CK-Setdb1 mice, another set 
of animals was exposed to mild, but inescapable foot shock that then induces a 
“helpless” state expressed as failure, or delay, in escaping the shock chamber 
when flight becomes possible (see Methods). Similar to the aforementioned FST 
and TST, learned helplessness (LH) represents a classical paradigm in 
preclinical depression research that has excellent predictive validity for 
antidepressive effects in humans (Willner, 1984). Notably, LH-related escape 
deficits and concomitant loss of hippocampal spine synapses potentially persist 
for days or even weeks, while subchronic treatment with conventional 
antidepressant restores escape behaviors and synaptic connectivity (Hajszan et 
al., 2008). In the current study, mice (from line #1 and #2) were exposed during 
two training sessions to mild but inescapable electric foot shock in a chamber, 
then depression-related behavior was measured by the ensuing increase in 
escape latencies 24 hours, and 7 days after training. Independent of genotype, 
untrained animals typically escaped in < 5 sec from the shock chamber (data not 
shown). By comparison, 24 hours after the second day of helplessness training, 
escape latencies on average approached 20 sec for both genotypes. However, 7 
days after training, CK-Setdb1 but not the control mice showed a significant, > 
50% reduction in escape latencies (Fig. 1-2c).  
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Because clinical antidepressants work by preventing future as well as curtailing 
ongoing depressive episodes (Blier et al., 2007), we treated another set of 
animals before and during LH training subchronically (10 days) with the 
antidepressant, tranylcypromine (TCP), a monoamine oxidase inhibitor (MAOi), 
and then measured helplessness 24 hours and 7 days after training and drug 
treatment.  Indeed, 24 hours after training, escape latencies in saline-treated 
animals increased to approximately 20 sec, but were < 10 sec in the TCP-treated 
animals of both genotypes; this drug effect was highly significant by two-way 
ANOVA.  However, 7 days after LH training and exposure to TCP, significant 
effects became apparent both for treatment and genotype, with a dramatic 
reduction in escape latencies particularly in TCP-treated CK-Setdb1 mice (Fig. 1-
2c). We conclude that CK-Setdb1 mice, like their wildtype counterparts, develop 
helplessness after the two training sessions, but subsequently recover more 
quickly while wildtype littermates retain the initial increase in escape latencies for 
at least 7 days. Notably, one week after LH training, the reduction in escape 
latencies mediated by the transgene was of similar magnitude when compared to 
TCP, one of the most effective antidepressant drugs currently available (Thase 
and Sachs, 2000) (compare saline (SAL) treated CK-Setdb1 with TCP-treated 
wildtype at 7 days, Fig. 1-2c). These antidepressive phenotypes were specific as 
transgenic mice showed no changes in stimulant-induced locomotor sensitization 
and anxiety-related behaviors (Supplementary Fig. 1-2). 
Learning and memory of CK-Setdb1 mice 
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The accelerated recovery of escape behaviors after LH training in the transgenic 
animals could reflect: (i) an antidepressive phenotype, (ii) a more generalized 
alteration in the retention of foot shock-associated memories or (iii) a deficit in 
shock sensitivity or perception. However, the latter two possibilities were ruled 
out because shock reactivities across a range of currents (0.05 – 0.7mA) did not 
differ between CK-Setdb1 and control mice (Fig. 1-3a). Furthermore, shock-
associated memories in passive avoidance and fear conditioning paradigms were 
completely preserved (Fig. 1-3b,c). Passive avoidance, defined by the increase 
in latency to cross from a bright into a dark chamber in which the animal was 
previously exposed to a single foot shock persisted, independent of genotype, for 
at least 7 days (Fig. 1-3b). Likewise, freezing behaviors resulting from foot 
shocks administered within a specific context or a tone (Maren, 2001)  were 
indistinguishable between CK-Setdb1 and control mice when measured within 24 
hours, or up to 7 days after conditioning (Fig. 1-3c).   
Unexpectedly, however, CK-Setdb1 mice outperformed wildtype littermates in 
additional memory tests. These included superior spatial memory in probe trials 3 
and 7 days after animals learned the position of a fixed hidden platform in 
opaque water (simplified Morris Water Maze) and improved novel object 
recognition 24 hours after exposure (Supplementary Methods and 
Supplementary Fig. 1-3). Because CK-Setdb1 mice exhibit normal acquisition 
and retention of shock-related memories and fear behaviors as well as improved 
spatial and object recognition memory, one can conclude that the accelerated 
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recovery and reinstatement of escape behaviors after learned helplessness 
training, and the decrease in despair-related immobility indeed represents an 
antidepressive phenotype. 
Setdb1 occupancy in chromatin is limited but includes multiple glutamate 
receptor genes  
The behavioral changes in two independent CK-Setdb1 mouse lines would 
suggest that transgenic Setdb1, in addition to the hyper(tri)methylation of H3K9 
at pericentric repeats (Fig. 1-1g), affects chromatin structure and function at 
genes regulating neuroplasticity. To explore this, we profiled Setdb1 occupancies 
with a (non-repeat) tiling array (ChIP-Chip) covering mouse chromosomes 6, 8 
and 16 excluding DNA repeats.  Initial rationale to choose this particular 
chromosomal array was to include mouse chromosome 16 sequences syntenic 
to a portion of human 22q11.2 conferring high risk for affective disorder and 
psychosis as a microdeletion (DiGeorge/Velo-cardio-facial/22qDS) syndrome 
(Mukai et al., 2008). Owing to the lack of anti-Setdb1 antibodies with sufficient 
specificity for ChIP, we took advantage of the myc-epitope fused to Setdb1 cDNA 
in the CK-Setdb1 transgene. Pull-down of crosslinked chromatin with an anti-myc 
antibody (that did not cross react with 49kD wildtype myc, see Methods) 
confirmed presence of 180kD myc-Setdb1 in extracts from CK-Setdb1 forebrain, 
but no myc immunoreactivity, 180 kD or otherwise, was detectable in tissue 
homogenates or chromatin preparations from wildtype which served as the 
negative control for ChIP-Chip (Supplementary Fig. 1-4a). No Setdb1 signals 
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were found within 22qDS sequences. Instead, when explored with a 600 bp 
sliding window, mycSetdb1 occupancies across chromosomes 6/8/16 were 
limited to altogether 70 sites (Supplementary Table 1-1). Among these were 33 
gene hits and strikingly, 45% (15/33) were located within 30 KB from an 
annotated transcription start site (TSS) (Table 1-1). This finding is consistent with 
the notion that Setdb1 is associated with repressive chromatin remodeling and 
transcriptional inhibition (Schultz et al., 2002; Seum et al., 2007). Among the 33 
genes targeted by Setdb1 were (i) Grin2a and Grin2b, the sole two N-methyl-D-
asparate (NMDA) receptor subunits represented on the array, and (ii) Grid2, 
encoding the delta-2 receptor. Because 3 of the altogether 4 ionotropic glutamate 
receptor genes represented on chromosomes 6/8/16 (Grid2; Grik1; Grin2a,b) 
were targeted by Setdb1, Gene Ontology (GO) revealed a > 200-fold, highly 
significant enrichment (P < 10-5) for genes regulating the excitatory postsynaptic 
membrane potential (GO:0060079). From this, we draw several conclusions: 
chromosomal occupancies of Setdb1 methyltransferase are (i) overall extremely 
limited, (ii) frequently located within 30 KB from transcription start sites and (iii) 
include a subset of glutamate receptor genes.  
Setdb1 epigenetically regulates a chromosomal loop structure at Grin2b  
Repressive chromatin remodeling by Setdb1, is mediated, in part, by physical 
interaction with the KAP1 (KRAB-associated protein 1, or TRIM28/TIF1b/KRIP1) 
transcriptional corepressor (Ayyanathan et al., 2003). Indeed, KAP1 deletion is 
associated with decreased H3K9 methylation in forebrain (Jakobsson et al., 
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2008).  We monitored KAP1 occupancies at the Grin2b locus. KAP1-ChIP on 
forebrain of adult mice showed peak levels within 15KB from the TSS followed by 
a broader distribution spread at least 60KB into the Grin2b gene (Fig. 1-4a). This 
binding profile contrasted with the much shorter, ~ 1KB Setdb1-target sequence 
located 30 KB downstream from the TSS (red bar in Fig. 1-4a).  
To better understand these phenomena, we mapped physical interactions within 
the first 50KB of Grin2b, by employing chromosome conformation capture 
technology (3C) (Dekker, 2008) in undifferentiated and differentiated neuronal 
cultures derived from Nestin+ precursor cells of embryonic rat forebrain (Huang 
et al., 2007). Indeed, a chromosomal loop formation was detected (Fig. 1-4b), 
tethering a part of 3rd intron around the Setdb1-target site (which showed 
moderate enrichment for KAP1, see Fig. 1-4a) to a portion of the same intron 
positioned approximately 18KB further upstream that was highly enriched with 
KAP1 (gray shaded area in Fig. 1-4a,b). This loop was the sole interaction 
consistently observed in 3/3 neural precursor and 6/6 neuronal cultures. 
Therefore, the Setdb1 target site at Grin2b is in close proximity to a chromosomal 
loop. 
Setdb1 is associated with KAP1, a corepressor recruited by Krüppel-associated 
(KRAB) box zinc finger (DNA binding) proteins (KRAB-ZFPs), several of which 
are expressed in brain (Jakobsson et al., 2008).  Interestingly, there are two 
KRAB recognition motifs within the Setdb1 target site, and both ends of the loop 
structure combined harbor at least 8 putative KRAB binding sites (Fig. 1-4b). 
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This would suggest that KRAB-KAP1 complexes, organized as oligomers (Peng 
et al., 2000a; Peng et al., 2000b), play a role for the formation or maintenance of 
the Grin2b loop (Fig. 1-4c). 
Down-regulated Grin2b expression and altered NMDA receptor function in 
CK-Setdb1 hippocampus and prefrontal cortex  
Notably, the Setdb1-target site, positioned in the 3rd intron of mouse Grin2b was 
selectively hypermethylated (H3K9me2) in CK-Setdb1 mice (Fig. 1-4a), which 
could indicate repressed gene expression. To explore this, we checked mRNA 
and protein levels in the hippocampus and prefrontal cortex, two brain regions 
frequently implicated in the neuronal circuitry of depression (Krishnan and 
Nestler, 2008). Indeed, CK-Setdb1 mice showed a significant 20% reduction in 
Grin2b RNA, while levels for Grin2a (which has a Setdb1-target site in the 3’ 
portion of the gene) or the constitutive subunit, Grin1, remained unaltered (Fig. 
1-5a). Furthermore, Grin2b but not Grin2a protein was up to 50% decreased in 
CK-Setdb1 hippocampus and prefrontal cortex, in comparison to wildtype 
littermates and after normalization with different “housekeeping genes” (Fig. 1-
5b). 
The NMDA receptor subunit, Grin2b, is found in synaptic and extrasynaptic 
NMDA receptor complexes (Thomas et al., 2006). To explore whether decreased 
Grin2b alters NMDA receptor function in CK-Setdb1 mice, we recorded NMDA 
currents in whole cell patch clamp on somata of acutely dissociated hippocampal 
neurons from P18-P21 animals. To visualize myc-Setdb1 expressing neurons, 
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we crossed the CK-Setdb1 line #1 to mice expressing green fluorescent protein 
(eGFP)-conjugated histone H2B under control of the CK promoter (Jiang et al., 
2008a). In the hippocampus (including the CA sectors), 99.4% (723 out of 727 
counted) GFP+ neuronal nuclei were also myc-Setdb1+ (Supplementary Fig. 1-
5). Recordings included GFP+ and GFP- cells with pyramidal neuron-like 
morphology. When NMDA currents were evoked with NMDA concentrations 
ranging from 1 µM to 3 mM, in the presence of 15 µM CNQX to block non-NMDA 
glutamate receptors, current amplitudes were maximum with 1 mM NMDA and 
rapidly declined with lower concentrations (Fig. 1-5c). Dose response curves, 
including the EC50, were nearly equivalent between wildtype (324 µM) and CK-
Setdb1 mice (310 µM) (Fig. 1-5c). Because the EC50 for NMDA is higher for 
receptors containing Grin2a and Grin2b, as compared to the remaining NR2 
subunits, Grin2c and Grin2d (which are expressed at low levels in P18 and older 
hippocampus) (Laurie and Seeburg, 1994), we conclude that CK-Setdb1 animals 
do not show a generalized loss of NMDA receptor function. However, 
heteromeric receptors comprised of Grin2b subunits (together with the 
constitutive subunit Grin1) show slower current decay rates as compared to 
Grin2a (Vicini et al., 1998; Tovar et al., 2000). Therefore, we compared Ca2+-
independent desensitization kinetics in CK-Setdb1 and wildtype neurons. NMDA 
currents were evoked around -60 mV holding potential by co-application of 500 
µM NMDA with saturating concentrations of glycine (200 µM) and fast and slow 
current decay were best fit by a single exponential (Fig. 1-5d). Indeed, in 10 out 
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of a total of 16 recorded GFP+ neurons from CK-Setdb1 mice, τ values (the rate 
of current decay) were distributed between 0.3 and 1.0 sec, and another, smaller, 
cluster (5 of 16) ranged between 1.0 to 1.3 sec. Notably, the averaged τ for 
GFP+ neurons from CK-Setdb1 mice was 0.76 ± 0.13 s, N = 16, which 
represented a significant, two-fold decrease when compared to GFP- neurons 
from the same animals/cultures (1.48 ± 0.31 s, N = 8) (Fig. 1-5d).   Furthermore, 
the averaged τ from control animals (genotype CK-H2BeGFP+ / CK-Setdb1-) 
was 1.34 ± 0.13 s, n= 19 (Fig. 1-5d), but differences between the τ’s from GFP+ 
and GFP- neurons of these mice were less than 15% and not significant (data 
not shown). Together, these findings suggest that Setdb1 represses Grin2b 
expression in neurons, thereby affecting NMDA receptor subunit composition and 
desensitization kinetics.  
Discussion 
We have discovered that mice expressing in adult forebrain neurons high levels 
of Setdb1 histone methyltransferase show antidepressive phenotypes, in the 
context of normal fear conditioning but improved novel object recognition and 
spatial memories. It is remarkable that mice with forebrain-specific ablation of 
KAP1—which associates with Setdb1 and NuRD histone deacetylase to regulate 
facultative heterochromatin (Ayyanathan et al., 2003; Sripathy et al., 2006; Peng 
and Wysocka, 2008)—exhibit H3K9 demethylation at a limited set of genes in 
conjunction with elevated levels of anxiety and stress-related impairments in 
memory tasks very similar to those applied here (Jakobsson et al., 2008). This 
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broadly opposing pattern of behavioral changes in mouse KAP1-Setdb1 loss- 
and gain-of-function models, in the absence of more generalized neurological 
alterations, highlights the therapeutic potential of up-regulated Setdb1 activity in 
brain.  
Two of the 33 genes identified as Setdb1-targets on chromosomes 6,8 and 16 
confer genetic risk for mood disorder in selected populations—GPM6a (Boks et 
al., 2008), encoding a glycoprotein on neuronal membranes and GRIN2B (Fallin 
et al., 2005; Avramopoulos et al., 2007), the NMDA receptor subunit expressed 
at low or moderate levels in adult forebrain. Because drug-induced inhibition, or 
genetic ablation of Grin2b decreases depression or anxiety scores in mice 
(Maeng et al., 2008; von Engelhardt et al., 2008), downregulated Grin2b 
expression and altered NMDA receptor function in prefrontal cortex and 
hippocampus of CK-Setdb1 mice could explain the observed decrease in 
behavioral despair and the accelerated recovery from learned helplessness. 
While learning and memory is compromised in animals with a complete genetic 
ablation of Grin2b in hippocampus and other forebrain areas (von Engelhardt et 
al., 2008), a partial inhibition of expression, as observed in CK-Setdb1 mice of 
the present study, may have been less detrimental. Finally, it is likely that the full 
range of Setdb1-mediated behavioral changes is elicited by repressive chromatin 
remodeling at additional genes. 
The molecular mechanisms that direct Setdb1 to multiple glutamate receptor 
genes, in the context of an overall highly restricted genomic occupancy, remain 
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to be explored. Of note, the Drosophila ortholog, dSetdb1, preferentially binds to 
the fourth chromosome, a 5MB structure harboring the fly’s sole metabotropic 
glutamate receptor gene (Seum et al., 2007; Tzeng et al., 2007). Given that 
NMDA receptor inhibition, including blockade of GRIN2B/NR2B, is emerging as 
an effective intervention for treatment-resistant depression (Berman et al., 2000; 
Zarate et al., 2006; Preskorn et al., 2008), further exploration of Setdb1-regulated 
histone methylation, including its relation to higher order chromatin structures at 
NMDA receptor genes, bears the potential to design radically novel therapies for 
a major psychiatric disorder. 
Materials and Methods 
Animals. All experimental procedures were approved by the Institutional Animal 
Care and Use Committee of the University of Massachusetts Medical School.  
Animals were housed in groups of 2-4 per cage with food and water ad libitum 
under 12-hour light/dark cycle. 
Generation of CaMKII-Setdb1 (CK-Setdb1) transgenic mice A myc-tagged 4.6 
kb mouse ESET/Setdb1 full length cDNA fused to simian virus (SV40) late 
polyadenylation signal (SV40 pA), was isolated from plasmid pCS2-MT-ESET (a 
gift from Dr. Liu Yang, University of Arkansas for Medical Sciences) (Yang et al., 
2003) and inserted into modified pMM403 vector under the CaMK II alpha 
promoter (Choi et al., 1991; Mayford et al., 1996b; Mayford et al., 1996a). Before 
this step, a Kozak sequence (5’-AGCCACCATGG-3’) was inserted to replace (5’-
TTAAAGCTATGG-3’) in pCS2-MT-ESET. The transgene vector was linearized 
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with two SfiI cuts and injected into C57BL/6 x SJL F2 hybrid mouse embryos at 
the UMASSMED Transgenic Animal Modeling Core. Integration of transgenes 
into the mouse genome was confirmed by genomic PCR with two different primer 
sets amplifying transgene specific sequence (CK-Set: left 5’-
GAGCGATGATCACTTGTGGA-3’, right 5’-GCCGATCAACATAAGCCACT-3’; 
Set: left 5’-CTGGCAAGGGTGTTTTCATT-3’, right 5’-
CTCCAGGCCTTCTTTGTCTG-3’). 2 out of 4 different founder lines showed 
widespread expression of the transgene in forebrain (see also Results). These 
two colonies were kept in different housing rooms. For each experiment, CK-
Setdb1+/0 mice were compared to gender-matched littermate controls housed in 
the same cage.   
Behavioral assays. For each of the behavioral tests, each CK-Setdb1+/0 mouse 
was matched to a wildtype littermate of the same gender housed in the same 
cage as the transgenic animal. For tail suspension, forced swim, learned 
helplessness, passive avoidance and fear conditioning, only adult male mice 
were used. For Morris water maze and novel object recognition tests, both 
genders were included. All tests were scored blindly. 
Tail suspension test. Animals were suspended with a paper clip wrapped with 
tape around the tail, 0.75 cm from the tip; then hung from a mounted hook 50 cm 
above the tabletop. Animals showing tail climbing behaviors were removed from 
this test. The whole test was videotaped, and the time spent immobile during a 
six-minute testing period was then scored by a trained reviewer. 
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Forced swim test. Animals were placed into a 4 L pyrex beaker (13 cm diameter, 
24 cm height) filled with 22 oC water, 17 cm deep.  The time spent immobile 
during a six-minute testing period was measured. Immobility, evaluated by a 
blind reviewer, was defined according to the criteria as described (Schramm et 
al., 2001).  
Learned helplessness. A learned helplessness (LH) paradigm was conducted 
as described (Caldarone et al., 2004). During training, learned helplessness was 
induced in mice by administering 120 inescapable foot shocks (IES) for 4 sec 
each at 0.3 mA once every 26 sec over a 1-hr session in a closed compartment 
(Gemini Avoidance System, San Diego Instruments). Training was given in two 
sessions spaced approximately 24 hrs apart.  Next, 24 hrs and 7 days after the 
second training session, animals were tested in a shuttle escape task. Animals 
were given 30 escape trials with 30-sec intervals between each trial. The initial 5 
trials featured a 0.3 mA shock with an open door to an adjacent “safe” 
compartment for escape. Shock stimulus was terminated at escape or after 26 
secs, whichever was shorter. The remaining trials proceeded similarly; however, 
the escape route (door opening) was presented 2 sec after shock onset. Shock 
stimulus was terminated at escape or after 24 sec, whichever was shorter. The 
latency to each escape was recorded, and the averaged latency from 30 trials 
was used to measure both learned helplessness as well as the subsequent 
recovery from helplessness.  
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Shock reactivity. Animals were placed into an inescapable testing chamber, and 
subjected to foot shocks with 2-sec duration at 0.05, 0.1, 0.3, 0.5, and 0.7 mA 
with 28-sec interval. Animal behaviors induced by foot shock were monitored and 
scored as: flinching-1, vocalizing-2, running-3, and jumping-4. Shock reactivity 
was presented as the total score after each trial of shock. 
Passive avoidance. The test apparatus consisted of two chambers divided by 
an automatic guillotine door: one chamber was illuminated by an overhead light 
and the other kept in dim light. On habituation day, animals were introduced into 
the lighted chamber with the connecting door closed. After 2 sec, the door was 
opened and the animals were allowed to free explore for 5 min. On training day 
(24 hr after habituation day), the animals were re-introduced into the lighted 
chamber with the connecting door open. The latency (pre-shock) to enter the dim 
chamber was recorded. Once the animal entered into the dim chamber, the door 
was closed, and an inescapable foot shock (2-sec duration, 0.5 mA) was 
delivered in the dim chamber. Animals were left in the dim chamber for 10 
additional sec after shock, and then returned to the homecage. Next, animals 
were then tested 24 hr or 7 days after training. On testing days, animals were 
introduced into the light chamber with the connecting door open, and the latency 
to enter the dim chamber was recorded with a maximum testing time of 5 min. 
Contextual and tone-induced fear conditioning. A fear conditioning protocol 
was used as described (Reijmers et al., 2006), with minor modifications.  On day 
1, animals were subjected to a training trial by placing them in a chamber 
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(Gemini Avoidance System, San Diego Instruments) with context A: methanol-
scented, grid-floor, cue light on.  After 3 min of baseline freezing measurement 
(data not shown), four tone-shock pairings were presented 1 min apart.  Each 
pairing consisted of a 20 sec tone simultaneously ending with a 2 sec, 0.5 mA 
inescapable foot shock. Animals remained in the chamber for 1 min after the last 
tone-shock pairing with freezing activity measured during the final 40 seconds 
(Data not shown). On day 2, the day 1 training trial was repeated with the first 3 
min used to measure 24 hr context freezing. On day 3, animals were tested for 
24 hr tone freezing in a chamber with context B: ethanol-scented, cue light off, 
left chamber wall covered with orange craft foam and back chamber wall with 
white/blue-striped contact paper.  After 3 min baseline, 20 sec tone was 
presented and freezing during the tone was measured.  On day 7, animals were 
placed in context A for 3 min to measure 7 days context freezing; on day 8, 
animals were placed in context B and the day 3 trial was repeated to measure 7 
days tone freezing. In sham control groups, animals received tone, but no shock 
stimulus in day 1 and day 2 trials. Behavior was recorded and freezing (bouts of 
>1 sec immobility) was scored. 
Novel object recognition. A non-matching-to-sample learning task was used to 
study as described (Bevins and Besheer, 2006). Mice were firstly submitted to a 
10 min training session in an apparatus (30 x 30 x 30 cm, L x W x H), where they 
were exposed to two identical objects (“to-be-familiar objects”). After prescribed 
intervals (1 or 24 hours), mice were submitted to a 5 min testing session in the 
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same apparatus, in which one of the “familiar objects” was replaced by a “novel 
object”, and the object exploration time with either the “familiar object” (Tfamilar) or 
the “novel object” (Tnovel) was measured separately. The object exploration was 
scored when the mouse sniffed or directly contacted the object with nose. 
Standing, sitting or leaning on the object were not scored. The object recognition 
was reflected as more exploration time with the “novel object” than the “familiar 
object”, which was a positive difference score (Tnovel- Tfamiliar) or a discrimination 
ratio (Tnovel/( Tfamilar+ Tnovel)) above 0.5. 
Morris Water Maze. The water maze consisted of a large white circular tank 
(diameter 4 feet) and a circular escape platform (diameter 12 cm). The tank was 
filled with room temperature water, which was covered by small white 
polystyrene beads (diameter 0.1-0.2 mm). The escape platform was located in 
one quadrant of the maze and submerged 2 cm below the surface of the water. 
Three different extra-maze visible cues were placed on the room walls. Mice 
were first introduced into the water maze and submitted to a visible-platform task 
on day 0, in which the location of the platform was indicated by a black flag. Mice 
were then submitted to hidden-platform tasks, 4 times daily for 12 days (from day 
1 to day 12). In each hidden-platform trial, mice were placed into the water maze 
with a random starting location in four different quadrants. Mice were permitted to 
swim freely until they located and climbed onto the platform. If the mice did not 
finish the task in 90 sec, they were assisted to the platform and left there for 10 
secs. After prescribed intervals (3, or 7 days), mice were submitted to probe trials 
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(on day 15 and day 19), in which the escape platform was removed. Mouse 
behavior was assessed by Ethovision video tracking software and certain 
parameters like swim speed, the latency to locate platform (or in probe tests, the 
latency to first visit of previous platform zone), and the time spent in four different 
quadrants, were measured for further data analysis. 
Immunohistochemistry. 18 μm coronal sections from perfusion-fixed (by 
phosphate-buffered 4% paraformaldehyde) adult brain were processed free-
floating for anti-myc (A-14) (Santa Cruz, #sc-789) immunoreactivity, which was 
detected with diaminobenzidine using the ABC kit (VectorLabs). This antibody 
recognizes epitopes of human c-myc but cross-reactivity with the murine 
homolog was not detectable (Fig. 1-1c,f and Supplementary Fig 1-1. and 
Supplementary Fig. 1-4a) For anti-myc immunofuorescence, fresh frozen brain 
sections were fixed with 100% methanol at -20 °C for 10 min. In addition, nuclei 
isolated from brain tissue homogenates in hypotonic solution were fixed, spread 
on slides and air dried, and then stained for anti-myc and anti-NeuN (Chemicon, 
MAB377). 
Immunoblotting. Samples were homogenized directly in 1x Laemmli buffer with 
1x Complete Proteinase Inhibitor (Roche Applied Science, #11697498001), 
incubated at 37 °C for 10 min, and centrifuged at 13,500 g for 5 min at 4°C. The 
supernatant was denatured at 95 °C for 5 min, electrophoresed on a 4%–20% 
linear gradient Tris-HCl gel, and then transferred to nitrocellulose membrane. 
Immunostainings were performed with anti-myc (Santa Cruz, #sc-789), anti-
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Setdb1 (Upstate, #07-378), anti-Grin2b (Chemicon, #AB1557p), anti-Grin2a 
(Chemicon, #AB1555p), and for loading controls, anti-Gapdh (Abcam, #ab9485) 
and modification-independent histone H3 (Upstate, #07-690). Immunoreactivity 
was detected with peroxidase-conjugated secondary antibody in conjunction with 
chemiluminesence-based film autoradiography. For quantification, Quantity-One 
(Biorad) software was used. 
Real-time RT-PCR. Total RNA was extracted from cerebral cortex, striatum, or 
hippocampus of mice brains using RNeasy Lipid Tissue Mini kit (QIAGEN, 
#74804), and then subjected to SYBR green based one-step RT-PCR using 
Taqman One-Step RT-PCR Mix Reagents (Roche, #4309169). Primers are listed 
in Supplemental Table 1-2. 18S rRNA was used as an internal control 
(Schroeder et al., 2007). Quantification as previously described (Huang et al., 
2006). 
Chromatin immunoprecipitation. Samples were fixed in 1% formalin for 5 min 
at room temperature, sonicated at power level 6 (Branson Sonifier 250) in ice 
water (6 runs of 1 min impulse with 1 min resting interval) (Supplementary Fig. 
1-4b), pre-cleaned, and then subjected to anti-H3K9me3 (Upstate, #07-442), 
anti-H3K9me2 (Upstate, #07-441), anti-myc (Santa Cruz, #sc-789), or anti-KAP1 
(Abcam, #ab22553) immunoprecipitation. Control samples were processed with 
normal rabbit IgG (Upstate, #12-370), in parallel to samples with specific 
antibodies. For H3K9me3 ChIP, input DNA and immunoprecipitated DNA were 
subjected to slot-blot hybridization using a 32p labeled oligonucleotide probe 5’ 
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GGACC TGGAA TATGGC GAGAA A 3’ targeting mouse major satellite DNA. 
For H3K9me2 and KAP1 ChIP, input DNA and immunoprecipitated DNA were 
subjected to SYBR green based real time PCR using primers amplify different 
regions of Grin2b gene locus. See Supplementary Table 1-2 for detailed 
information of primers.  
Mouse tiling array. A mouse tiling array, GeneChip Mouse Tiling array 2.0R F 
array (Affemetrix, #900899), which is comprised by approximately 6.5 million 25-
mer oligonucleotide probes covering chromosomes 6, 8, and 16, was used. After 
anti-myc ChIP, soluble DNA was amplified with a whole genome amplification 
system (Sigma, WGA2) according to a protocol from the Farnham lab 
(http://www.epigenome-noe.net/researchtools/protocol.php?protid=30) with slight 
modifications. After library preparation, DNA samples were amplified by 14-
cycles of unbiased PCR with universal primers, with 0.4 mM dUTP (Sigma, 
D0184). Amplified dUTP DNA was then fragmented into around 69 bp by uracil 
DNA glycosylase digestion and end-labeled with biotin using GeneChip WT 
Double Stranded DNA Terminal Labeling Kit (Affymetrix, #900812) 
(Supplementary Fig. 1-4c). Approximately 7.5 μg of biotin-labeled DNA was 
hybridized to single tiling array. Hybridization, washing, staining, and scanning 
were conducted according to Affymetrix chromatin immunoprecipitation protocol 
(P/N 7002238).  
Significant signals were calculated using the MAT algorithm as described 
(Johnson et al., 2006). Genomic windows of 600 bp were scored (MATscore) and 
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P values were calculated based on the estimates of the nonenriched null 
distribution of the MAT scores. A false discovery rate (FDR) for a region was 
calculated as the number of positive regions (above MATscore threshold) divided 
by the number of negative regions (below MATscore threshold). Genomic sites 
and genes with significantly higher signals in CK-Setdb1 than in wildtype 
samples were listed in Table 1-1 and Supplemental Table 1-1. 
Rat neuronal stem cell culture. Nestin-positive neural precursors were cultured 
from E14.5 SASCO SD rat forebrain, expanded with fibroblast growth factor 2 
(FGF2) in the medium, then differentiated in the absence of FGF2 with or without 
valproic acid (VPA),  as described (Huang et al., 2007). In brief, frozen 
undifferentiated cells were thaw and plated out at 1.2–1.4 × 106 per 100-mm dish, 
and kept in culture with the presence of 10 ng/ml of FGF2 for 2 days. To induce 
differentiation, FGF2 was then withdrawn and cells were kept in culture with or 
without 0.5 mM VPA for another 4 days before harvest. 
Chromosome Conformation Capture (3C). To trap chromosomal loop 
formations within the proximal 50 KB of rat Grin2b (which includes sequences 
homologous to mouse Grin2b sites occupied by KAP1 and Setdb1 (Fig. 1-4b), 
3C was performed as described with minor modifications(Miele and Dekker, 
2009). In brief, rat neuronal cell cultures were treated with 2% formaldehyde to 
trap chromosome conformation. Cellular nuclei were then extracted, digested 
with Hind III at 37 °C over night, and subsequently ligated with T4 DNA ligase at 
16 °C for 2 hours. After reverse crosslinking, proteins were removed by 
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proteinase K digestion, DNA was purified and tested for potential interaction by 
PCR using 8 primers, positioned 5’ to 3’ on the sense strand (Fig. 1-4b and 
Supplemental Table 1-2). Each primer was positioned approximately 250 bp or 
less from the 3’ end of each Hind III restriction site. PCR products were resolved 
in 2% GTG agarose gels, DNA bands with expected size were excised, purified, 
sub-cloned into TOPO-PCR4 vector (Invitrogen, #K4575-J10), and subjected to 
sequencing analysis. Primers that did not reveal products in the 3C assay were 
probed with proper reverse primers and intact (non-digested) rat genomic DNA to 
confirm functionality and control for any false negative results in the 3C.  
KRAB regulatory elements. To determine putative KRAB regulatory elements 
in sequences trapped by 3C, we used the program Genomatix 
(http://www.genomatix.de/).  The sequences corresponding to this gene region in 
different species including rodents and human were tested for sequences related 
to regulatory elements of matrix family V$ZNFP (MateBase site from 
GenomatixPortal, applying the flexible parameters with core similarity  (setup-
0.70) and Matrix similarity (setup-Opt.-0.10). Series of putative 25-27 bp 
elements with core similarity 0.75-1.00 and matrix similarity 0.71-0.85 were 
identified in rodent and human Grin2b/GRIN2B gene in close proximity or within 
the loop shown in Fig. 1-4b.  
Electrophysiology. Hippocampus slices from age-matched postnatal day 18-21 
CK-Setdb1+/0 /CK-H2BeGFP+/0 and control mice were prepared as previously 
reported (Martin and Siggins, 2002). Animals were anesthetized with 4% 
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halothane, decapitated and the brains rapidly transferred into an ice-cold (3-4 oC) 
oxygenated, low-calcium HEPES-buffered salt solution (mM): 234 sucrose, 2.5 
KCl, 2 NaH2PO4, 11 glucose, 4 MgSO4, 2 CaCl2, 1.5 HEPES. A tissue block 
containing the hippocampus was glued to a teflon chuck and cut transversally 
with a vibroslicer (Vibratome 1500; Vibratome, MO USA). The slices (350 µm 
thick) was incubated for up to 6 hours at room temperature (20-22 oC) in a 
gassed (95% O2 and 5% CO2) NaHCO3-buffered saline solution (mM): 116.4 
NaCl, 1.8 CaCl2, 0.4 MgSO4, 5.36 KCl, 0.89 NaH2PO4, 5.5 glucose, 24 NaHCO3, 
100 glutathione, 1 nitro-arginine, 1 kynurenic acid. pH was adjusted to 7.35 with 
NaOH, 300-305 mOsm/l. After one hour of incubation, the region of the 
hippocampus was dissected out with the aid of a dissecting microscope, and the 
tissue was incubated for 15 min in an oxygenated (100% O2 with constant stirring) 
HEPES-buffered solution in the inner chamber of a Cell-Stirr flask (Wheaton, 
Millville, NJ; USA) containing protease XIV (1 mg/ml) and (mM): 136 NaCl, 0.44 
KH2PO4, 2.2 KCl, 0.35 NaH2PO4, 5.5 Glucose, 10 HEPES, 100 glutathione, 1 
nitro-arginine, 1 kynurenic acid and 1 pyruvic acid (pH = 7.35 with NaOH, 300-
305 mOsm). The temperature of this solution was kept constant (36 oC) by a 
circulating water bath in the outer chamber of the flask.  
After enzymatic digestion, the tissue was transferred into a centrifuge tube and 
rinsed twice with a Na+-isethionate solution. The tube was then filled with 5 ml of 
Na+-isethionate solution and, after 10 min, the tissue was triturated using fire-
polished Pasteur pipettes with successively smaller tip diameters. The 
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supernatant was plated onto a 35 mm Petri dish placed on the stage of the 
inverted fluorescence microscope. The cells were allowed to attach to the bottom 
of the dish for at least 10 min before replacing the Na+-isethionate solution with 
normal Locke’s solution composed of (mM): 142 NaCl, 2 KCl, 1 CaCl2, 23 
glucose, 15 HEPES, 10 glucose (pH = 7.35 with NaOH, osmolarity 300 mOsm/l).  
Whole-cell recordings. Standard whole-cell recording methods were used as 
described (Mayford et al., 1996b). Both GFP+ and GFP- cells with pyramidal 
morphology were selected and applied for recording. Briefly, patch electrodes 
were pulled from borosilicate 1.5 mm capillary glass (Warner Instrument, CT 
USA) on a Brown-Flaming P-97 puller (Sutter Instruments, CA USA) to a final 
resistance of 2-4 MΩ. The electrodes were filled with a solution that consisted of 
(mM): 120 KMeSO4, 11 EGTA, 10 HEPES, 0.5 CaCl2, 2Na2-ATP, 0.2 Na3-GTP, 
12 phosphocreatine (pH = 7.35 with KOH; osmolarity, 270-275 mOsM). The 
capillaries were first filled through the tip and then backfilled with the recording 
solution. We recorded in voltage-clamp mode with an EPC-10 double amplifier 
from HEKA Electronik (Lambrecht/Pfalz; Germany). The recordings were filtered 
at 5 kHz and digitized at 1 kHz. Liquid junction potentials were not corrected but 
are estimated to be +4 mV.  
Control and drug-containing solutions were applied by gravity at a rate of 1.5 ml/s, 
using a rapid 3-barrel capillary superfusion device (Warner Instrument; USA) with 
the pipette tips placed about 200 µm from the recorded cell. Each capillary had a 
tip diameter of 500 µM and the distance from center to center was 700 µM. The 
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pipette assembly was attached to a motor, allowing fast lateral motions controlled 
by PatchMaster 2.32 (HEKA Electronik, Germany), the acquisition software.  
Dose-response curves were obtained as follows: after recording a stable current, 
pyramidal-like neurons were exposed for 4 sec to increasing concentrations of 
NMDA (1 to 3000 µM) in the presence of a saturating (200 µM) concentration of 
glycine, glycine receptor antagonist (picrotoxin, 1 µM) and 15 µM CNQX to block 
non-NMDA glutamate receptors, and peak current amplitude was measured. To 
avoid current inactivation, drugs were applied every 60 sec. Glycine, glutamate, 
NMDA, and picrotoxin were purchased from Sigma (St Louis, MO).  
Dose-response curves was fitted with a Hill equation as follows: I = 
Imax/[1+(EC50/C)n], where   I, Imax, C, EC50, and n are agonist activated current, 
maximal agonist-activated current, agonist concentration, the concentration for 
50% of the response, and the Hill coefficient, respectively. NMDA current 
desensitization was measured on NMDA currents evoked by co-application (4 
sec) of 500 µM NMDA and 200 µM glycine at –60 mV holding potential. The 
current decay was fitted with a single exponential using an analysis software 
(FitMaster 2.35; HEKA Electronik Germany), and tau values were used to 
construct a scattered plot. 
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Figure 1-1: Expression and activity of Setdb1 methyltransferase in wildtype 
and CK-Setdb1 transgenic mice. Developmental downregulation of Setdb1 (a) 
protein and (b) RNA in wildtype cerebral cortex; embryonic day (E) 12.5, 15.5, 
18.5, postnatal (P) 7, and Adult (8+ weeks). Bar graph (b) normalized to 18S 
rRNA (mean±S.E.M.), n = 5/age group. *p<0.05; one-way ANOVA. (c) Anti-myc 
immunoreactivity in brain sections of 8 week CK-Setdb1 and wildtype mice (line 
#1) as indicated. Notice transgene expression in (left) layers II-VI of cerebral 
cortex (Cx), and (right) Striatum (Str), Hippocampus (Hipp) but not Cerebellar 
cortex (Cbc). Scale bars: Cx, Str, 100 μm; Hipp 200 μm, Cbc 150 μm. (d) Anti-
myc (red) immunofluorescence in neuronal nuclei (anti-NeuN, green) (arrows), 
but not in non-neuronal nucleus  (dotted line); blue, DAPI. Scale bar, 10 μm. (e) 
Bar graphs showing elevated Setdb1 RNA levels (mean±S.E.M.) in Cx, Str and 
Hipp of  8 week old CK-Setdb1, as compared to wildtype littermate;  n=4-
5/genotype. *p<0.05, **p<0.01, Student’s t-test. (f) Immunoblots showing (top) 
180 kD anti-myc signal in prefrontal cortex (PFC), Str and Hipp of 8 week old CK-
Setdb1 (+) but not wildtype (-) mice, (bottom) increased 180kD anti-Setdb1 signal 
in transgenic cerebral cortex; each lane loaded with 20 mg protein. (g) 
Representative slot blot from anti-H3K9me3 and IgG control ChIP hybridized with 
major satellite DNA probe, and bar graphs  summarizing chip-to-input ratio 
(mean±S.E.M.) for H3K9me3. Notice 50% increase in CK-Setdb1 mice, 
compared to wildtype littermates; n = 12/group, *p<0.05, Wilcoxon signed rank.  
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Figure 1-2: Antidepressive phenotypes in CK-Setdb1 mice. (a,b) Bar graphs 
showing total immobility times, shown as mean ± SEM., for (a) tail suspension 
and (b) forced swim tests in 2-3 month old male CK-Setdb1 mice (black) and 
wildtype littermates (white bars). a (b) from line #1, ( #2). Notice significant 
decrease in behavioral despair/immobility; n=8-11 / test and genotype. *(**)p < 
0.05 (0.0005), Student’s t test. (c) Accelerated extinction of learned helplessness 
in 2-10 month old male CK-Setdb1 mice. Top:  Time lines for shock training and 
escape behavior testing in the absence of treatment (left) or daily injections of 
tranylcypromine (TCP) (10 mg/kg) or saline (SAL), (right) as indicated. Bottom: 
Bar graphs show averaged escape latencies (30 trials / animal) 24 hours and 7 
days after second training. Data are expressed as mean ± SEM, n=8- 9/ 
genotype (lines #1, #2 pooled) and treatment. Left graph illustrates significant 
reduction in escape latency in drug-naive CK-Setdb1 mice on day 7; **p<0.01, 
Dunn’s test, Q = 3.77. Right graph illustrates significant drug (TCP vs. SAL), (F (1, 
15)=27.35, p<0.005), but not genotype effect at 24 hours after training, and 
significant drug and genotype effect 7 days after training (TCP vs. SAL, F (1, 15) 





Figure 1-3. Shock-associated reactivity and memory functions are 
preserved in CK-Setdb1 mice.  (a) Scatter plot showing shock reactivity scores 
(flinching, vocalization, running and jumping, see Methods) in CK-Setdb1 and 
littermate control mice exposed to an escalating current (0.05 – 0.7 mA, 2 sec 
each), as indicated. (b) Passive avoidance, bar graph showing latency (sec) to 
enter dim chamber before (pre), and 24 hr or 7 days after (post) single foot shock. 
(a,b) n=8-11 for each test / genotype. (c) Fear conditioning, (Top) experimental 
design, including time lines for context and tone. (Bottom) Bar graphs showing 
(Left) context and (Right) tone induced total immobility/freezing in CK-Setdb1 and 
wildtype littermates over the course of 180 and 20 sec for context and tone, 
respectively, 24 hr and 7 days after shock or sham trainings as indicated. Notice 
no significant differences between transgenic and control mice. Data shown as 




Figure 1-4: Grin2b chromatin architecture. (a) Top: Schematic overview for 
110KB 5’ and 3’ from mouse Grin2b transcriptional starting site, including 
position of primer pairs (i-x) used for (bottom left) KAP1-ChIP on wildtype, and 
(bottom right) H3K9me2-ChIP on wildtype and CK-Setdb1 forebrain. Gray area 
marks chromatin with very high KAP1 levels and red bar marks 760 bp Setdb1-
target of mouse intron 3 (homolog to rat intron 1). Notice H3K9 hypermethylation 
at Setdb1 binding site in CK-Setdb1 mice. Data shown as mean±SEM. n = 5 -11 
per group. *p<0.05, student’s t-test. (b) Chromosome Conformation Capture (3C): 
(Top) Overview for rat Grin2b, including Hind III (H) restriction map, (gray) KAP1 
and (red) Setdb1 binding sites as described for mouse. Dashed lines = primer 
pairs probed for potential interactions in 3C assay. All primers positioned 5’ to 3’ 
on sense strand. Middle left: Representative agarose gel picture showing 230 bp 
PCR product of primers 5-7 using 3C libraries from undifferentiated (U) and 
differentiated (D) cultures (treated ± VPA) from rat E14.5 telencephalic precursor 
cells. Middle right: 3C technique applied to Grin2b (from left to right: before, after 
Hind III digestion, after ligation) Orange triangles mark KRAB recognition motifs 




Figure 1-5:  Altered Grin2b expression and NMDA receptor function in CK-
Setdb1 mice. (a) Bar graphs: Hippocampal Grin2b, Grin2a, Grin1 RNAs in adult 
CK-Setdb1 and wildtype. n= 6-8 per genotype, *p<0.05, Student’s t test. (b) 
Grin2b, Grin 2a proteins (upper bands, ~ 180 kDa), Gapdh (middle, ~ 40 kDa), 
histone H3 (lower, 17 kDa) immunoblots from hippocampus (Hipp) and prefrontal 
cortex (PFC) of 2-3 month old CK-Setdb1 and wildtype littermates. Notice 
significant decreases of Grin2b in CK-Setdb1 mice.  n=7-15 per genotype per 
group. **p<0.01. Two-way ANOVA. (c) (Left) Representative currents evoked by 
NMDA with different concentrations from 1μM to 3 mM from 3 hippocampal 
neurons. Horizontal bar represents timing of drug exposure. (Right) Dose 
response plot of peak NMDA currents averaged from 8 and 10 neurons from CK-
Setdb1 (filled circle) and wildtype (open circle), respectively. (d) (Left) 
Representative individual currents of 3 pyramidal cell-like hippocampal neurons 
in response to 500 μM NMDA. Red lines represent single exponential fits of 
current desensitization, values (sec) are indicated above the traces. (Right) 
Scatter plot showing individual NMDA current desensitization rate (open circle) 
and averaged rate (black dot) from GFP+ and GFP- neurons from CK-Setdb1 
and wildtype. Notice significantly faster desensitization in GFP expressing 
neurons of CK-Setdb1 hippocampus as (i) compared to GFP negative cells 
(genotype: CK-Setdb1+ / CK-H2BeGFP+) (Q=3.88) and (ii) neurons (both GFP 
+,-)  from control animals with genotype CK-Setdb1- / CK-H2BeGFP+ (Q=3.19). 






Table 1-1: Gene hits from anti-myc ChIP-chip. 
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Supplementary Figure 1-1 Expression of mycSetdb1 transgene in line #2 
CK-Setdb1 mice. Anti-myc immunoreactivity in brain sections of transgenic or 
wildtype mice. Notice that CK-Setdb1 (line #2) mice, but not the controls, show 
robust labeling in cerebral cortex (Cx), striatum (Str), and hippocampus (Hipp), 





Supplementary Figure 1-2 Gross neurological function and anxiety-related 
behavior was not altered in CK-Setdb1 mice. (a) Body weight, (b) Locomotor 
activity, and (c) Rotarod performance of adult CK-Setdb1 and wildtype mice. 
Data shown as mean ± SEM. N = 16-31 per genotype. *P < 0.05 as compared to 
wildtype. Student’s t-test. (d) Locomotor sensitization after repeated daily 
injections of cocaine (COC) (10 mg/kg) for 10 days (day 1 to day 10) in adult CK-
Setdb1 and wildtype mice. Data shown as mean ± SEM. n = 8 per genotype. 
Baseline activity was measured after single injection of saline (SAL) the day (day 
0) before cocaine treatment. (e) Light-dark exploration and (f) Elevated plus 
maze performance of adult CK-Setdb1 and wildtype mice. Data shown as mean 




Supplementary Figure 1-3 Spatial memory and novel object recognition in 
CK-Setdb1 and wildtype mice. (a) Novel object recognition in CK-Setdb1 and 
wildtype mice, presented as (Left) Difference score = T(novel)-T(familiar) and 
(Right) Discrimination ratio = T(novel)/ (T(novel)+T(familiar)). Notice that 24 hrs, 
but not 1 hr after training, CK-Setdb1 showed better object recognition memory, 
compared to wildtype littermates. n = 25-26 per genotype, age and gender 
matched. *P < 0.05, one-way ANOVA. (b) (Top) Time lines for Morris water maze 
training and probe trials. (Bottom) Graphs (left) show latency to climb onto 
platform (days 0-12); or to first entry into (former) platform zone in probe trials 3 
days (day 15) or 7 days (day 19) after training. n = 12 per genotype, **(*)P < 
0.01(0.05), two-way ANOVA. Notice that CK-Setdb1 mice, but not wildtype 
littermates, maintained the shorter latencies from the training period. Right bar 
graph shows average velocity (cm/sec) on days 0 and 19 for CK-Setdb1 and 




Supplementary Figure 1-4 Quality controls for anti-myc ChIP-on-chip. (a) 
Representative blot shows ~180 KD mycSetdb1 immunoactivity in “Input” and 
anti-myc (myc) chromatin immunoprecipitates (ChIP) from CK-Setdb1 (+), but not 
wildtype (-) forebrains. Protein extracted from cerebral cortex (Cx) and anti-H3 
(H3) ChIP material was processed as positive and negative controls. (b) 
Chromatin fragmentation by sonication after formalin fixation. Representative gel 
picture shows the range of DNA fragments ranging from 500 bp to 1KB. (c) 
Biotin-end labeling of DNA material for mouse tiling array detection. Notice the 
gel mobility shift between unlabeled (U) and biotin-end labeled (B) samples from 




Supplementary Figure 1-5  
mycSetdb1 expression in CK-Setdb1/CK-H2BeGFP hippocampus.  
(a) Representative images show co-expression of myc (red) immunoreactivity 
and GFP (green) in nuclei extracted from hippocampus of CK-Setdb1/CK-
H2BeGFP mice; blue = DAPI counterstain. Scale bar, 25 μm. (b) Acutely 
dissociated cells with from hippocampus. Representative samples of (top) GFP 
positive and (bottom) negative neurons, which were both included in NMDA 




Supplementary Table 1-1:  





Supplementary Table 1-2: Primers used for RT-PCR, XChIP, and 
Chromosome Conformation Capture (3C).  
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CHAPTER III: SETDB1-MEDIATED HISTONE 
HYPERMETHYLATION IN NEURONS DOES NOT RESCUE THE 
PHENOTYPE OF MECP2-DEFICIENT MICE 
This work was conducted under the direction of Dr. Schahram Akbarian. My 
contribution in this work was to execute the majority of the experiments including 
generation of genetic engineered mice, behavioral assays, in situ hybridization, 
primary culture of mouse cortical neurons, chromatin immunoprecipitation, 
Western blot, immunostainings and RT-PCR. Anouch Matevossian contributed 
by conducting FACS sorting, chromatin immunoprecipitation, and PCR running. 
Yin Guo contributed by conducting Immunohistochemistry and animal tagging 
and genotyping. The manuscript was primarily prepared by Dr. Akbarian, while I 
contributed to the Materials and Methods, Figures and Legends. 
Abstract 
Rett syndrome (RTT), a neurodevelopmental disorder of early childhood, is 
primarily caused by mutations in the gene encoding methyl-CpG-binding protein 
2 (MECP2). Various molecular functions have been ascribed to MECP2, 
including the regulation of histone modifications associated with repressive 
chromatin remodeling, but the role of this mechanism for the pathophysiology of 
RTT remains unclear. Here, we explore whether or not overexpression of the 
histone H3-lysine 9 specific methyl-transferase, Setdb1, which is 
developmentally regulated and normally present only at low levels in mature 
brain, rescues the RTT-like phenotype of Mecp2 deficient mice. A myc-tagged 
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Setdb1 cDNA was expressed through the tau locus for ubiquitous expression in 
CNS neurons, or as a transgene under control of the calcium/calmodulin-
dependent protein kinase II (CK) promoter, which is primarily active in postmitotic 
neurons of forebrain. However, neither the CK-Setdb1 transgene nor the 
tauSetdb1 allele extended the shortened life span, or improved neurological 
deficits of mice with a brain-specific deletion of Mecp2 during prenatal 
development. Moreover, although transgenic mice showed a 60% increase of 
trimethylated H3K9 in pericentromeric heterochromatin, a known Setdb1 target 
site in brain, levels of trimethylated H3K9 at pericentromeric repeats were fully 
maintained in differentiated neurons from symptomatic Mecp2 mutant mice. 
These results suggest that neuronal chromatin in RTT brain is not affected by a 
generalized deficit in H3K9 trimethylation. We conclude that artificial up-
regulation of this repressive chromatin mark is not sufficient to rescue the 
phenotype of Mecp2 mutant mice.  
Introduction 
Rett syndrome (MIM 312750) is a neurodevelopmental disorder of early 
childhood in which affected girls show developmental regression and various 
types of neurological dysfunction, often after a 6-18 month symptom-free period, 
while boys typically do not survive beyond early postnatal life (Weaving et al., 
2005; Chahrour and Zoghbi, 2007). The majority of cases are due to mutations in 
the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Presently, treatment 
options for RTT patients address only the symptoms (Kerr and Burford, 2001; 
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Percy, 2002), while effective prevention and/or cure will require a better 
understanding of the underlying molecular pathology. To this end, important 
clues have been provided by studies on genetically engineered mice. For 
example, a Rett-like phenotype is induced by conditional ablation of Mecp2 in 
neurons (Chen et al., 2001; Guy et al., 2001) , and rescued in Mecp2 null mutant 
mice with pan-neuronal expression of a Mecp2 cDNA (Luikenhuis et al., 2004). 
These findings underscore that Rett syndrome is a neuronal disease. Importantly, 
activation of Mecp2 expression—even after mutant mice became symptomatic—
resulted in a robust phenotypic reversal (Guy et al., 2007). Based on these 
findings, it was suggested that the neurological deficits in this disorder may not 
be irreversible (Guy et al., 2007). It remains to be determined, however, which of 
the various molecular actions ascribed to MeCP2—including remodeling of 
facultative or constitutive heterochromatin, as well as a more complex role in the 
regulation of gene transcription, mRNA splicing, and structuring of higher order 
chromatin (Nan et al., 1998; Ng and Bird, 1999; Chahrour and Zoghbi, 2007; 
Jordan et al., 2007; Yasui et al., 2007; Chahrour et al., 2008; Kumar et al., 2008; 
Nelson et al., 2008)—are critical for the maintenance of neuronal health in 
wildtype mice and the development of disease in the Mecp2 deficient brain.  
Here, we test the hypothesis whether repressive chromatin modifications, 
specifically, tri-methylation of the histone H3-lysine 9 residue (H3K9me3), could 
rescue the phenotype of Mecp2 deficient mice. To investigate this, we 
engineered mice with neuron-specific expression of the histone H3-lysine 9 
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specific methyl-transferase, ERG-associated protein with SET domain (Eset), 
also known as SET domain, bifurcated 1 (Setdb1) (Schultz et al., 2002; Yang et 
al., 2002). Setdb1 contains, in addition to a SET and a Tudor domain, a methyl-
CpG-binding domain (Schultz et al., 2002; Yang et al., 2002; Ayyanathan et al., 
2003; Blackburn et al., 2003), and, like MeCP2 (Jones et al., 1998; Nan et al., 
1998), interacts with the mSin3-histone deacetylase (HDAC) co-repressor 
complex (Yang et al., 2003). In addition, Setdb1 is recruited to select genomic 
loci together with the nucleosome remodeling and deacetylation (NuRD) complex 
(Ayyanathan et al., 2003; Sripathy et al., 2006; Peng and Wysocka, 2008).  The 
two complexes, mSin3 and NuRD, share a number of proteins, including HDAC 1 
and 2 (Ng and Bird, 2000). Although MeCP2, in contrast to Setdb1, has no 
methyl-transferase activity, it is thought to regulate H3K9 methylation via its 
interaction with Suppressor of variegation 3-9 homolog 1 (Suv39H1) methyl-
transferase (Lunyak et al., 2002). Therefore, both Setdb1 and MeCP2 are 
implicated in repressive chromatin remodeling, but potentially involve different 
protein complexes.  
In the present study, we observed that expression of MeCP2 and Setdb1 
undergo dynamic changes during brain development, but in a strikingly opposite 
manner. Since levels of Setdb1 in the mature brain were much lower when 
compared to the pre- and postnatal developmental periods, we asked whether or 
not a persistent up-regulation of Setdb1 expression in adulthood could rescue 
Mecp2 deficient mice that typically develop symptoms several weeks after birth 
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(Chen et al., 2001; Guy et al., 2001; Shahbazian et al., 2002a) .  To address this 
question, we generated two independent mouse lines to express Setdb1 in 
differentiated neurons: either by a transgene driven by the calcium/calmodulin-
dependent protein kinase II (CK) promoter, or through the endogenous tau locus.   
Results 
Developmental expression profile of Setdb1 is opposite to Mecp2 
As described in CHAPTER II, the levels of Setdb1 mRNA and protein were 
downregulated during mouse brain development, which were highest at the 
earliest stage examined (E12.5), but then showed a progressive and significant 
decline in 8-12 week old (adult) cortex (Fig. 1-1a,b). The high expression of 
Setdb1 in the developing brain was further confirmed by in situ hybridization on 
E12.5 and E15.5 brains. The Setdb1 antisense  probe resulted in robust labeling 
throughout the developing brain (Fig. 2-1), including mitotic cells within 
proliferative layers, such as the ventricular zone, as well as postmitotic neurons 
residing in the cortical plate and other territories (Fig. 2-1). In contrast, labeling of 
sections from adult brain was weak and often not distinguishable from 
background (data not shown).  
To further test whether the observed downregulation of Setdb1 protein during 
development occurs within differentiating neurons, we monitored the temporal 
pattern of Setdb1 expression in primary neuronal cultures derived from E15.5 
mouse cortical plate (Fig. 2-2A). After 14 days of culture in vitro, Setdb1 
immunoreactivity was significantly decreased by more than 2-fold (Fig. 2-2B). In 
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contrast, during the same time period, levels of MeCP2 immunoreactivity showed 
a 14-fold, significant increase (Fig. 2-2C). The latter finding is in good agreement 
with earlier studies in rodent (Shahbazian et al., 2002b; Jung et al., 2003), 
monkey (Akbarian et al., 2001) and human brain (Shahbazian et al., 2002b) 
reporting that MeCP2 levels are up-regulated during the course of neuronal 
maturation. We conclude that expression of both Setdb1 and MeCP2 undergo 
dynamic changes in differentiating neurons of developing brain, though in a 
strikingly opposite manner. This observation, in view of the potential overlap in 
MeCP2 and Setdb1 function, led us to speculate that the RTT phenotype in adult 
Mecp2 deficient mice could be ameliorated by artificial expression of Setdb1 in 
mature neurons.  
CK-Setdb1 transgene does not rescue the phenotype of Mecp2 deficient 
mice 
Next, we crossed the CK-Setdb1 transgenic line 1 with Mecp2 conditional mutant 
mice for a Cre/loxP mediated deletion of the methyl-CpG binding domain (MBD) 
(Chen et al., 2001), which is encoded by exon 2 of Mecp2 isoform 1, or exon 3 of 
isoform 2, respectively (Kriaucionis and Bird, 2004; Mnatzakanian et al., 2004). 
As expected (Chen et al., 2001), conditional, Nestin-Cre mediated deletion of 
Mecp2 during prenatal brain development resulted in premature death beginning 
at 2 months of age, impaired motor coordination, and decreased locomotor 
activity (Fig. 2-3B-D). Furthermore, the Mecp2 deficient mice, which are of a 
mixed genetic background that includes C57Bl6/J, were significantly underweight 
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at 4 weeks of age (Fig. 2-3A), as previously reported for the mutants of that 
inbred line (Guy et al., 2001). At later ages, mutant weight became more variable 
(data not shown). Survival, motor activity and coordination, and body weight of 
CK-Setdb1 transgenic mice expressing wildtype MeCP2 were not significantly 
different from controls (Fig. 2-3). However, the transgene did not rescue the 
decrease in body weight, nor did it prevent neurological symptoms and 
premature death of Mecp2 mutant mice (Fig. 2-3). Instead, the most pronounced 
deficit in novelty-induced locomotion was observed in CK-Setdb1/Mecp2-/y mice, 
which showed a significant 40%, or 20% decrease in activity scores compared to 
wildtype controls, or Mecp2-/y animals, respectively (Fig. 2-3B).  
Expression of Setdb1 through the tau locus does not rescue the phenotype 
of Mecp2 deficient mice 
As described above, neuronal expression of Setdb1 in adult forebrain does not 
rescue the Rett-like phenotype of Mecp2 mutant mice. Of note, previous studies 
that utilized the CK promoter to rescue Mecp2 deficient mice yielded variable 
results (Alvarez-Saavedra et al., 2007; Giacometti et al., 2007; Jugloff et al., 
2008). In contrast, when Mecp2 cDNA is expressed under control of the promoter 
of the microtubule-binding protein tau, complete rescue is achieved (Luikenhuis 
et al., 2004). This may be due to the fact that expression through the 
endogenous tau locus is pan-neuronal, starting during prenatal development and 
continues throughout all postnatal stages and adulthood (Luikenhuis et al., 2004). 
Another advantage of the tau locus is that mice not expressing wildtype tau 
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protein appear in good health and without overt neurological defects (Harada et 
al., 1994; Dawson et al., 2001; Tucker et al., 2001; Denk and Wade-Martins, 
2007) other than subtle defects in motor coordination and fear conditioning  in 
some studies (Denk and Wade-Martins, 2007). 
To express Setdb1 through the endogenous tau locus, we fused the myc-tagged 
Setdb1 cDNA first with a neomycin resistance cassette, and then ligated it into a 
tau targeting vector as previously described (Luikenhuis et al., 2004), replacing 
the ATG start codon of wildtype tau and surrounding sequences (Fig. 2-4A). The 
targeting construct was electroporated into AB2.2 embyronic stem cells. From 
384 neomycin-resistant clones, 13 were targeted correctly, including clone 
#63D3 (Fig. 2-4B) that was passed through the germline to generate tauSetdb1 
mice. As expected, expression of 180 kDa myc-tagged Setdb1 in these knock-in 
mice was neuron-specific and present in all brain regions examined (Fig. 2-4C-E). 
As mentioned above, double-banding of the 180kDa immunoreactivity was 
observed at shorter exposure times (Fig. 2-4E).  
Next, we crossed the tauSetdb1 knock-in with Mecp2 conditional mutant mice. 
Similar to the experiments described above, the Mecp2 deficient mice of this 
outbred colony also showed significant deficits in motor coordination assayed by 
rotarod (Fig. 2-5A) and premature death starting around 8 weeks of age (Fig. 2-
5B). However, in this colony, the body weight of Mecp2 mutant was not different 
from controls (<2%, data not shown). Furthermore, the survival and motor 
coordination of tauSetdb1 knock-in mice expressing wildtype Mecp2 were not 
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significantly different from controls (Fig. 2-5A). However, the tauSetdb1 allele 
conferred a strong trend (Kaplan-Meier, p < 0.07) for further acceleration of 
premature death in Mecp2 mutant mice (Fig. 2-5B). This Rett-like phenotype was 
observed in both hetero- and homozygous tauSetdb1 knock-in mice (Fig. 2-5B 
legend and data not shown). Thus, neither the CK-Setdb1 transgene nor the 
tauSetdb1 knock-in allele ameliorated the symptoms induced by Mecp2 
deficiency.   
Levels of trimethyl H3-lysine 9 in pericentromeric heterochromatin are 
maintained in neurons from Mecp2 deficient brain 
Setdb1 histone methyl-transferase is specific for the H3-lyine 9 residue (Schultz 
et al., 2002; Wang et al., 2003). Mice with a monoallelic deletion of CREB-
binding protein (CBP) show de-repression of Setdb1 in adult brain, which results 
in hypertrimethylation of H3K9 in pericentric heterochromatin (Lee et al., 2008). 
As described, transgene-derived expression of myc-Setdb1 cDNA resulted in a 
significant, approximately 60% increase in heterochromatin-associated trimethyl-
H3K9 (H3K9me3) at pericentric repeats (CHAPTER II, Fig. 1-1g). Of note, 
MeCP2 is highly concentrated in pericentromeric heterochromatin (Lewis et al., 
1992). In the mouse, pericentric heterochromatin is mainly defined by tandem 
repeats of A/T-rich major satellite repeats comprised of approximately 105 copies 
of a 234 base-pair unit (Waterston et al., 2002). Among the various repressive 
histone methylation marks, H3K9me3 is highly and consistently enriched at sites 
of major satellite repeats in different cell types (Martens et al., 2005). Importantly, 
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immunoprecipitation studies revealed association of MeCP2 with Suppressor of 
variegation 3-9 homolog 1 (Suv39H1) (Lunyak et al., 2002), a histone methyl-
transferase essential for H3K9 trimethylation at pericentric repeats (Peters et al., 
2001). Together, these findings imply that MeCP2, bound to the methylated 
CpG’s of the major satellite, regulates H3K9me3 at these repeats via an 
interaction with Suv39H1. Therefore, loss of MeCP2 could affect orderly 
methylation of H3K9 in chromatin surrounding major satellite repeats. However, 
until now this hypothesis has not been tested in Mecp2 deficient brain. 
Importantly, MeCP2 is localized almost exclusively in mature neurons (Akbarian 
et al., 2001; Chen et al., 2001; LaSalle et al., 2001; Shahbazian et al., 2002b; 
Jung et al., 2003), which reside in brain together with glia and other cells mostly 
in a 2:1 – 1:2 ratio (Herculano-Houzel et al., 2006; Sherwood et al., 2006); 
therefore, a conclusive assessment of MeCP2 association with neuronal 
heterochromatin would require separation from non-neuronal elements. Here, we 
extracted neuronal nuclei from whole forebrain of 8 week old Mecp2-/y and male 
controls; at this stage, the Mecp2 mutant mice already are symptomatic and 
show deficits in locomotor activity (Fig. 2-3B). The neuronal nuclei were sorted 
via FACS after immunotagging with anti-NeuN antibody (Fig. 2-6A, B), 
employing a previously described protocol (Jiang et al., 2008a). Subsequently, 
neuronal nuclei were subjected to digestion with micrococcal nuclease and, after 
ChIP with anti-H3K9me3 antibody, the mono-nucleosomal DNA from 
immunoprecipitates, input, and no antibody control samples were blotted without 
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prior amplification. Overall DNA yields of input samples were similar between 
mutant and control samples, indicating that the nucleosomal organization of the 
genome is grossly maintained in the absence of MeCP2 (data not shown). 
Furthermore, levels of H3K9me3 at major satellite repeats were completely 
preserved in neurons from Mecp2 mutant brain, compared to wildtype controls 
(Fig. 2-6C). We conclude that MeCP2 is not essential for the establishment or 
maintenance of the H3K9me3 mark at major satellite DNA in neuronal nuclei. 
Discussion 
Using genetically engineered mice, we demonstrate that persistent up-regulation 
of neuronal Setdb1 expression in adult brain results in hypertrimethylation of 
H3K9 at pericentromeric repeat DNA, but does not rescue the phenotype of 
Mecp2 deficient mice. Furthermore, we show that H3K9 trimethylation levels 
remain unaltered in pericentromeric chromatin of neuronal nuclei from 
symptomatic Mecp2 deficient mice. Therefore, loss of Mecp2 is not associated 
with a generalized deficit in H3K9 tri-methylation at DNA repeats in diseased 
neurons.  
The latter finding is in good agreement with recent findings that methylation of 
H3K9 and other histone residues are maintained at normal levels (or show only 
minimal changes) in bulk chromatin extracted from whole tissue of selected brain 
regions of Mecp2 null mutant mice (Urdinguio et al., 2007) or peripheral blood 
cells of RTT patients (Kaufmann et al., 2005). On the other hand, a study utilizing 
quantitative immunofluorescence for H3K9me3 found a generalized decrease in 
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Mecp2 deficient neuronal nuclei, although the punctate staining of 
heterochromatic foci was preserved in the mutants (Thatcher and LaSalle, 2006). 
Likewise, no consistent changes in global histone acetylation were reported in 
Mecp2/MECP2 deficient brain (Shahbazian et al., 2002a; Thatcher and LaSalle, 
2006; Urdinguio et al., 2007), blood cells, or cell lines (Wan et al., 2001; Balmer 
et al., 2002; Kaufmann et al., 2005), and it remains possible that this variation 
may be in part due to differences in the genetic background and type of 
Mecp2/MECP2 mutations, or even the specific histone molecules or residues 
examined.  
In the present study, genetically engineered mice with a sustained up-regulation 
of Setdb1 expression in adult brain displayed hyper-trimethylation of H3K9 in 
neuronal chromatin, yet did not develop an overt neurological phenotype. 
However, in the Mecp2 mutant mice, the CK-Setdb1 transgene resulted in a 
significant worsening of motor deficits (Fig. 2-3B), and the tauSetdb1 allele 
conferred a strong trend (P < 0.07) towards further shortening of the survival time 
of these animals (Fig. 2-5B). These findings effectively rule out the hypothetical 
possibility that the artificial elevation of H3K9 methylation in our Setdb1 
overexpressing mice was not sufficiently high in order to compensate for the loss 
of MeCP2. Instead, one could draw the conclusion that while brains of mice with 
normal levels of MeCP2 were able to tolerate the artificial hypermethylation of 
H3K9, the same manipulation applied to the Mecp2 deficient brain led to 
additional dysfunction and decompensation.  
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Our finding that neuronal overexpression of Setdb1 is tolerated in an otherwise 
normal brain, but not in RTT, is of interest from the viewpoint of a related finding 
in Huntington’s disease, a neurodegenerative disorder caused by polyglutamine 
repeats which is associated with transcriptional dysregulation (Butler and Bates, 
2006). Interestingly, both Setdb1 expression and levels of H3K9me3 are 
increased in Huntington’s striatum, and may contribute to the neurological 
phenotype in genetic mouse models of the disorder (Ryu et al., 2006; Stack et al., 
2007; Lee et al., 2008). Therefore, when taken together with the findings 
presented here, it is possible that dysregulation of Setdb1-mediated histone 
methylation worsens neuronal disease in the Huntington’s brain, while a similar 
level of Setdb1 activity in normal brain does not result in an overt phenotype.  
To date, little is known about the molecular signaling pathways regulating Setdb1 
expression and function in brain. A number of chromatin-associated proteins that 
interact with Setdb1, including mSin3A (Yang et al., 2003), histone deacetylases 
(HDAC) 1 and 2 (Ng and Bird, 2000), and tripartite motif protein 28 (Trim28), also 
known as KAP-1 co-repressor (Schultz et al., 2002), are expressed at moderate 
or high levels in adult brain (Lein et al., 2007). Furthermore, gene deletion 
studies suggest that the histone acetyl-transferase, CREB-binding protein (CBP), 
inhibits Setdb1 expression in striatal neurons by limiting Ets-2 transcription factor 
activity (Lee et al., 2008). However, the precise role of Setdb1 in developing and 
mature brain, including its potential contribution to neurological disease, requires 
further investigation. Notably, in the Setdb1 overexpressing mice of the present 
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study, histone trimethylation at pericentric repeats was increased, which is in 
good agreement with a recent report linking CBP deficiency in brain to increased 
expression of Setdb1, which was accompanied by increased H3K9me3 and 
expansion of pericentric heterochromatin (Lee et al., 2008). Therefore, at least in 
brain, Setdb1 could be involved in the epigenetic regulation of pericentromeric 
satellites and other DNA repeats, in addition to its well described interaction with 
repressor and silencing complexes in euchromatin (Ayyanathan et al., 2003; 
Wang et al., 2003; Li et al., 2006a; Lyst et al., 2006; Takada et al., 2007; Wang et 
al., 2007).  Indeed, a role for Setdb1 in the regulation of DNA repeat chromatin is 
supported by the observation that this methyl-transferase is recruited by 
heterochromatin protein HP-1 to mediate histone methylation in repetitive DNA in 
various mammalian cell lines (Verschure et al., 2005), and at pericentromeric 
repeats in  murine embryonic stem cells lacking Suv(3)9h1/2 histone methyl-
transferase (HMTase) activity (Kourmouli et al., 2005).  Given that Suv(3)9h1 
interacts with MeCP2 (Lunyak et al., 2002), one could speculate that neuronal 
overexpression of this particular methyl-transferase—in contrast to the Setdb1 
experiments presented here—could rescue the RTT phenotype of Mecp2 mutant 
mice. However, because H3K9 methylation levels in the pericentromeric satellite 
repeats of mature neurons lacking Mecp2 did not differ from wildtype controls, a 
more likely scenario is that neither SuV(3)9h1/2 nor Setdb1 or other H3K9-
specific methyl-transferase transgenes prevent or ameliorate neuronal disease 
resulting from the loss of Mecp2.  
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Interestingly, there is evidence that in some brain regions, including the 
hypothalamus, Mecp2 both positively and negatively regulates a substantial 
number of mRNAs, suggesting that this protein may play a more complex role in 
transcriptional regulation than repression alone (Chahrour et al., 2008).  
Furthermore, a recent case diagnosed with the congenital variant of RTT was 
linked to a truncating mutation in FOXG1 (Ariani et al., 2008), which encodes a 
brain-specific transcriptional factor that interacts with JARID1B (Roesch et al., 
2008), a histone demethylase with specificity for the H3K4 residue (Xiang et al., 
2007; Yamane et al., 2007). H3K4 methylation is commonly associated with open 
chromatin and active gene expression (Shilatifard, 2008). Thus, it remains 
possible that artificial manipulation of histone methylation marks other than H3K9 
could profoundly modify the RTT phenotype of Mecp2 mutant mice.  
Materials and Methods 
Animals All experimental procedures were approved by the Institutional Animal 
Care and Use Committee of the University of Massachusetts Medical School 
(UMASSMED). Animals were housed in groups of 2-4 per cage with food and 
water ad libitum under 12-hour light/dark cycle. 
Generation of tauSetdb1 knock-in mice The PGKNeo resistant selectable 
marker from plasmid pK-11 (Frt-PGKNeo-Frt-Loxp-pBSSK) (Meyers et al., 1998) 
was inserted into the modified pCS2-MT-ESET (see above). Then, the myc-
Setdb1 cDNA was fused in-frame into the exon 2 of mouse Mapt (tau) locus, 
using pTau-KR plasmid containing 3.8 kb of tau genomic sequence (a gift from 
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Dr. Rudolf Jaenisch, Whitehead Institute, Cambridge, MA) (Luikenhuis et al., 
2004). For in-frame fusion, an adaptor (5’-ATCGATGGATATC-3’) with ClaI and 
EcoRV sites was introduced into pTau-KR, replacing a 14 bp fragment and ATG 
start codon of wildtype tau exon 2 (5’-ATGGCTGACCCTCG-3’). The targeting 
vector, pTau-MT-ESET, was linearized with SacII and electroporated into 129Sv-
strain AB2.2 embryonic stem (ES) cell lines at the Transgenic Animal Modeling 
Core. Neomycin-resistant clones were first pre-screened by PCR for correct 
insertion and further assayed by Southern blot with internal and external probes 
(see Results). The 5’ external probe was comprised of 447 bp fragment 
(subcloned from PCR product using wildtype AB2.2 ES cell DNA) located 2 kb 
upstream from the ATG condon of wildtype tau locus. The 3’ external probe was 
comprised of a subcloned, 982 bp fragments from wildtype ES cell DNA, located 
4.7 kb downstream from the ATG codon of wildtype tau. The internal probe was a 
1247 bp EcoRI/ BamHI fragment from the 5’-end of Setdb1 cDNA. Suitable 
clones (63F1, 63D3, 63E12) were used to generate chimeras by injection into 
C57BL/6 blastocysts at the Transgenic Animal Modeling Core. Chimeras were 
mated to C57BL/6J females; germline transmission was achieved with clone 
#63D3. tauSetdb1 was then crossed into the conditional Mecp2 knockout for the 
rescue experiments (see below). 
Mecp2 deficient mice with neuron-specific myc-Setdb1 expression  
For the rescue experiments, only male mice were included in this study.  
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CK-Setdb1 transgene To obtain CK-Setdb1/Mecp2-/y rescue mice, CK-Setdb1 
transgenic males (see CHAPTER II, “Material and methods”) were bred with 
Mecp2 2lox/2lox females. Then, CK-Setdb1+/o/Mecp2 2lox/2lox females were crossed 
with Nestin-Cre+/o transgenic males, and the following 4 genotypes were obtained 
at the expected frequencies: (1.) Mecp22lox/y (for simplicity, termed “wildtype” in 
the following), (2.) CK-Setdb1+/o/Mecp22lox/y (for simplicity, termed “CK-Setdb1” in 
the following), (3.) Nestin-Cre+/o/Mecp22lox/y (for simplicity, termed “Mecp2 -/y” in 
the following), and (4.) CK-Setdb1+/o/Nestin-Cre+/o/Mecp22lox/y (for simplicity, 
termed “CK-Setdb1/Mecp2-/y” in the following). After Cre-mediated ablation of 
Mecp2 coding sequences in this line of mutant mice , MeCP2 immunoreactivity 
becomes non-detectable,  as previously described (Chen et al., 2001) (Fig. 2-6).  
tauSetdb1 knock-in allele Previous studies found that tau knockout mice, or 
animals homozygous for various tau knock-in alleles, which effectively do not 
express wildtype tau protein, appear in good health and without overt 
neurological defects (Harada et al., 1994; Dawson et al., 2001; Tucker et al., 
2001; Denk and Wade-Martins, 2007). Therefore, both heterozygous and 
homozygous tauSetdb1 mice were included in this study. TauSetdb1+/o/Mecp2 
2lox/2lox females were crossed with tauSetdb1+/o/Nestin-Cre+/o males, and the 
following  genotypes were obtained at the expected frequencies: (1.) Mecp22lox/y 
(for simplicity, termed “wildtype” in the following), (2.) tauSetdb1/Mecp22lox/y (for 
simplicity, “tauSetdb1” in the following refers to both hetero- and homozygous 
knock-in animals), (3.) Nestin-Cre+/o/Mecp22lox/y (for simplicity, termed “Mecp2-/y” 
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in the following), and (4.) tauSetdb1/Nestin-Cre+/o/Mecp22lox/y (for simplicity, 
termed “tauSetdb1/Mecp2-/y” in the following). 
Behavioral tests 
Novelty-induced locomotion (ambulatory beam breaks) Locomotion was 
monitored in a rectangular test chamber (19.1x29.2x12.7cm) with clean bedding, 
using a photocell beam based computer detecting system (San Diego 
Instruments). Mice were placed into the test chamber for 90 minutes under 
standard room lighting conditions. The beam breaks were collected every 5 
minutes to evaluate the spontaneous locomotor activity. 
Rotarod Rota-Rod (UGO BASILE 47600) was used to measure motor 
coordination in mice. The rotarod was set up with a slow acceleration mode, in 
which the rotation speed is accelerated from 2 to 40 rpm in 5 minutes. During the 
training session, mice were subjected to 10 consecutive 5-min trials with a 5-min 
intertrial interval. The latency (sec) to falling off or, alternatively, making a full-turn 
rotation was recorded.  24 hours after training, mice were tested by receiving 3 
consecutive trials (at 5 min intervals), and the mean latency was used to present 
the performance. 
Additional Methods 
In situ hybridization Entire heads (Embronic day (E) 12.5), or whole brains 
(E15.5) were fixed with 4% phosphate-buffered paraformaldehyde (4% PFA) at 
4°C overnight, then frozen or paraffin-embedded for subsequent in situ 
hybridization. 18 µm sections from frozen samples, or 4 µm from paraffin-
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embedded samples were hybridized to 50 ng/50 μl of DIG-11-UTP labeled sense 
or antisense Setdb1 RNA probes at 60°C overnight, and then washed and 
digested with RNase A, and developed with the DIG Nuclei Acid detection kit 
(Roche, Indianapolis, IN), according to the manufacturer’s instructions. The 
Setdb1 probe was in vitro transcribed and was corresponding to a 347 bp 
fragment in 3’-end of Setdb1 cDNA. Similar studies were conducted on brains 
sections prepared from perfusion-fixed adult animals. 
Primary culture of mouse cortical neurons Cerebral cortex was dissected 
from C57Bl6/J mice at E15.5 and dissociated by trypsin digestion and trituration 
as described (Lesuisse and Martin, 2002). Cells (1.5×106 cells/well) were plated 
in poly-l-lysine coated 6-well plates, cultured in Neurobasal medium (Life 
Technologies) supplemented with B27 (GIBCO, #17504-044), 200 mM L-
glutamine, and 1% v/v penicillin and streptomycin (GIBCO, #15140). Antimitotic 
reagents, Uridine 5’-Triphosphate and 5-Fluoro-2-deoxy Uridine (10 mg/ml each) 
(Sigma) were added to limit glia proliferation. Cells were harvested after 2, 7, or 
14 days cultured in vitro (DIV), and then prepared for Western blot or 
immunofluorescence staining 
Immunohistochemistry Cultured cells were fixed with phosphate-buffered 4% 
PFA, permeabilized with 0.2% Triton X-100, blocked with 10% goat serum, and 
then incubated with primary antibody (anti- TuJI, -GFAP) overnight at 4 °C. The 
signal was detected by Alexa 488- or 594-conjugated secondary antibodies. 
Nuclei isolated from tissue homogenates in hypotonic solution (see below) were 
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fixed in  phosphate-buffered 4% PFA for 5 min, spread on slides and airdried, 
and then stained for anti-MeCP2 (Sigma, mouse monoclonal, clone men-8, 
directed against the N-terminus of MeCP2) and anti-NeuN immunofluorescence 
(Chemicon). In addition, 18 m coronal sections from perfusion　 -fixed adult brain 
were processed free-floating for anti-myc immunoreactivity, which was detected 
with diaminobenzidine using the ABC kit (VectorLabs). 
Immunoblotting Samples were homogenized directly in 1x Laemmli buffer with 
1x Complete Proteinase Inhibitor (Roche Applied Science, #11697498001), 
incubated at 37°C for 10 min, and centrifuged at 13,500 g for 5 min at 4°C. The 
supernatant was denatured at 95°C for 5 min, electrophoresed on a 4%–20% 
linear gradient Tris-HCl gel (Bio-Rad, Hercules, California), and then transferred 
to nitrocellulose membrane (Bio-Rad, 0.4 μm pore size). Immunostainings were 
performed with anti-c-myc (A-14) (Santa Cruz, #sc-789), anti-Setdb1 antibody 
(Upstate, #07-378), and anti-MeCP2 (Upstate #07-013, rabbit polyclonal, against 
MeCP2 C-terminus)  and, for loading controls, anti-GADPH (Abcam, #ab9485) 
and anti-histone H4 antibody (Upstate, #07-108). Immunoreactivity was detected 
with peroxidase-conjugated secondary antibody in conjunction with 
chemiluminesence-based film autoradiography (Super Signal West Dura Extend 
Reagent; Pierce, Rockford, Illinois). For quantification, Quantity-One (Biorad) 
software was used. 
Real-time RT-PCR Total RNA was extracted from cerebral cortex, striatum, or 
forebrain of mice brains using RNeasy Lipid Tissue Mini kit (QIAGEN, #74804) 
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according to manufactory’s protocol, and then subjected to SYBR green based 
one-step RT-PCR using Taqman One-Step RT-PCR Mix Reagents (Roche, 
#4309169). Two different sets of primers were designed to amplify approx. 100 
bp intron-spanning fragments in the 3’-end of Setdb1 cDNA. The primers were, 
18-2: left 5’-CTTCGCCGACCAGCTAGTAA-3’, right 5’-
GTTCCACTTTCCCCCTCACT-3’; 19-2: left 5’-CTTCTGGCTCTGACGGTGAT-3’, 
right 5’-GGAAGCCATGTTGGTTGATT-3’. The Bdnf primers used were: left 5’-
GCGCCCATGAAAGAAGTAAA-3’, right 5’-TCGTCAGACCTCTCGAACCT-3’. 
Quantifications were done with 18S rRNA as an internal control (Schroeder et al., 
2007).  
FACS-sorting of nuclei Nuclei were extracted from adult mouse forebrain, 
immunotagged with anti-NeuN, and sorted as described (Jiang et al., 2008a). 
Using this procedure, background immunofluorescence was minimal, and all 
sorted samples had a purity of 95% (NeuN+ nuclei) or more.  
Chromatin immunoprecipitation Samples were prepared either by micrococcal 
nuclease (MNase) digestion for native chromatin immunoprecipitation (NChIP) as 
described (Huang et al., 2006), or fixed by 1% formalin, sheared by sonication 
(Branson Sonifier 250) for XChIP. NChIP: In brief, MNase digestion was 
performed with a working concentration of 4U/mL at 37°C for 5 min. The resulting 
mono-nucleosomal preparation (approx. 146 bp) was precleaned by incubating 
with protein G agarose (which should also remove the antibodies used for NeuN 
labeling of nuclei), and then subjected to immunoprecipitation using anti-
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trimethyl-H3K9 (H3K9me3) antibody (Upstate, #07-442).  Typically, we used 6 – 
8 x106 FACS-sorted nuclei as input. XChIP: Samples were fixed in 1% formalin 
for 5 min at room temperature, sonicated at power level 6 (Branson, Danbury CT) 
in ice water (10 runs of 30 sec impulse with 1 min resting interval), pre-cleaned, 
and then subjected to H3K9me3 immunoprecipitation. Control samples included 
samples processed with normal rabbit IgG, in parallel to samples with specific 
antibodies. Input DNA and immunoprecipitated DNA were subjected to slot-blot 
hybridization using a 32p labeled oligonucleotide probe 5’ GGACC TGGAA 
TATGGC GAGAA A 3’ to label mouse major satellite DNA. 
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Figure 2-1. Widespread Setdb1 expression in the developing mouse brain. 
Representative images showing Setdb1 mRNA expression in coronal sections 
from frozen (A, B) or paraffin-embedded (C) tissue blocks at E12.5 (A) or E15.5 
(B, C).  Sections were hybridized with digoxigenin-labeled anti-sense (a) and 
sense (b) Setdb1 RNA probes. Notice robust expression in all compartments of 
the developing brain. Abbreviations: CI: cerebral cortex, layer 1, CP: 
caudoputamen, CxP: cortical plate, cpn: caudate putamen neuroepithelium, GP: 
globus pallidus, H: hippocampus, iz: intermediate zone, LV: lateral ventricle, ncn: 
neocortical neuroepithelium, SP: subplate, svz: subventricular zone (striatum), 
svzc: subventricular zone (neocortex), V3: third ventricle, nc: neocortical plate, iz: 
intermediate zone, vz: ventricular zone. Scale bars: 200 μm (A, B), 50 μm (C). 
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Figure 2-2:  Setdb1 expression profile is opposite to Mecp2 during the 
course of neuronal maturation. Primary cultures of cortical neurons from 
E.15.5 mouse cortical plate. A, Immunofluorescence of TuJ1 neuronal marker 
(red), GFAP (green) and DAPI (blue) at DIV 4.  B,C,  Representative blots (top) 
and bar graphs (bottom) showing Setdb1 (B) and MeCP2 (C) protein levels at 
DIV 2, 7, and 14. Data are expressed as mean ± SEM after normalization to H4. 
Notice opposing patterns of expression over time, as recognized by decline in 
Setdb1 and increase in MeCP2 expression. N = 4/age group. *p<0.05, #p<0.01 




 Figure 2-3: CK-Setdb1 does not rescue the RTT phenotype of Mecp2 
mutant mice. A, Body weight (at 4 weeks of age); B, locomotor activity (8 weeks 
of age); and C, rotarod performance (11 weeks of age) of wildtype, CK-Setdb1, 
Mecp2-/y and CK-Setdb1/Mecp2-/y. N=23-31/genotype (locomotor activity), N=13-
16/genotype (rotarod). *p<0.05 (Mecp2-/y), #p<0.01 (CK-Setdb1/Mecp2-/y) as 
compared to wildtype; *p<0.05 (CK-Setdb1/Mecp2-/y) as compared to Mecp2-/y, 
one-way ANOVA. D, Kaplan-Meier survival curves. N=19-24/genotype. Notice no 
improvement in neurological deficits (A-C) or prolonged survival (D) of CK-




Figure 2-4: tauSetdb1 mice. A, Targeting vector, including myc-tagged Setdb1 
cDNA (myc-Setdb1), neomycin resistance cassette (NEOR), and homologous 
flanking sequences of Mapt (tau) (gray box). Insertion of myc-Setdb1-NEOR 
cassette at tau exon 2 ATG start (marked by vertical line). Locations of 5’-
external (1), internal (2) and 3’-external (3) probes used for Southern blot 
analysis as indicated. B: BamHI; E: EcoRI. B, Representative images showing 
Southern blot analysis of WT and targeted embryonic stem cell clones (F1, D3, 
G11, E12) after digestion with BamHI or EcoRI. a) Hybridization with the internal 
probe (2) results in a 9887-bp band for the targeted allele (ki). b) Hybridization 
with the 5’-external probe (1) results in a 9175-bp WT band and a 4432-bp band 
for the targeted allele. c) Hybridization with the 3’-external probe (3) results in a 
9175-bp WT band and a 6768-bp band for the targeted allele. C, 
Immunohistochemical stains with anti-myc antibody, notice labeling of neuronal 
nuclei in cerebral cortex (a), striatum (c), hippocampus (e) and cerebellum (g) of 
tauSetdb1 mice;  (b, d, f, h) show corresponding sections from wildtype controls. 
Scale bar, 10 μm. D, Bar graphs showing Setdb1 mRNA expression in cerebral 
cortex (a) and striatum (b) from wildtype and tauSetdb1 mice. N=3-4/genotype. 
#p<0.01, one-way ANOVA. E, Anti-myc immunoblot showing expected 180kDa 
band in cerebral cortex (CC), striatum (Str), hippocampus (Hipp), cerebellum 
(Cbl), thalamus (Thal), hypothalamus (Hypo), periaqueductal gray (PAG), and 




Figure 2-5: tauSetdb1 does not prevent premature death of Mecp2 deficient 
mice. A, Rotarod performance from wildtype, tauSetdb1, Mecp2-/y, and 
tauSetdb1/Mecp2-/y at 12 weeks of age. N=9-17/genotype. *p<0.05 as compared 
to Control, one-way ANOVA. B, Kaplan-Meier survival curves. N=11-25/genotype. 
The group of tauSetdb1/Mecp2-/y mice was comprised of 8 hetero- and 17 
homozygous tauSetdb1 knock-in mice. Notice left shift in survival curve of 
tauSetdb1/Mecp2-/y mutant mice (Kaplan-Meier, P<0.07). Notice no significant 





Figure 2-6: H3K9 tri-methylation is normal in neuronal heterochromatin of 
the Mecp2 deficient brain. A, Representative image showing 
immunofluorescence of MeCP2/DAPI counterstain (a/b, c/d, green/blue), and 
NeuN/DAPI (e/f, g/h, green/blue) in nuclei after hypotonic extraction from adult 
Mecp22lox/y/Nestin-cre conditional knockout (Mecp2-/y) (a/b, e/f) and wildtype (c/d, 
g/h) forebrains. Notice lack of MeCP2 immunoreactivity in the mutants. Scale bar, 
10 μm. B, Representative FACS scatter plots from (a) negative control (NeuN-) 
processed without NeuN antibody, and (b) sample processed with NeuN 
antibody (NeuN+). Only the population of nuclei in sector P3, showing robust 
immunofluorescence, were collected during FACS. C, Chromatin of FACS-sorted 
NeuN+ nuclei from wildtype and Mecp2-/y were subjected to anti-H3K9me3 ChIP, 
and then processed together with input by slot-blot hybridized to major satellite 
DNA probe. Bar graph showings no changes in H3K9me3 levels in 
pericentromeric heterochromatin of neuronal nuclei extracted from 8 weeks old 




CHAPTER IV: ISOLATION OF NEURONAL CHROMATIN FROM 
BRAIN TISSUE 
The work presented in this chapter is reproduced from a study by Jiang et al., 
published in BMC Neurosci. (Jiang et al., 2008a). 
This work was conducted under the direction of Dr. Schahram Akbarian, and it is 
with gratitude to him and the other authors that I reproduce these data for the 
purposes of this dissertation. My contribution in this work was to together with Dr. 
Akbarian and Hsien-Sung Huang conduct conception and study design, and to 
carry out experiments including generation of transgenic mice, microarray assay 
and FACS sorting. Anouch Matevossian contributed by conducting FACS sorting, 
chromatin immunoprecipitation, and PCR running. Juerg Straubhaar contributed 
by conducting microarray data analysis. The manuscript was primarily prepared 




DNA-protein interactions in mature brain are increasingly recognized as key 
regulators for behavioral plasticity and neuronal dysfunction in chronic 
neuropsychiatric disease. However, chromatin assays typically lack single cell 
resolution, and therefore little is known about chromatin regulation of 
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differentiated neuronal nuclei that reside in brain parenchyma intermingled with 
various types of non-neuronal cells. 
Results:   
Here, we describe a protocol to selectively tag neuronal nuclei from adult brain – 
either by (anti-NeuN) immunolabeling or transgene-derived histone H2B-GFP 
fusion protein – for subsequent fluorescence-activated sorting and chromatin 
immunoprecipitation (ChIP). To illustrate an example, we compared histone H3 
lysine 4 and 9 methylation marks at select gene promoters in neuronal, non-
neuronal and unsorted chromatin from mouse forebrain and human cerebral 
cortex, and provide evidence for neuron-specific histone methylation signatures. 
Conclusions:  
With the modifications detailed in this protocol, the method can be used to collect 
nuclei from specific subtypes of neurons from any brain region for subsequent 
ChIP with native/un-fixed or crosslinked chromatin preparations. Starting with the 
harvest of brain tissue, ChIP-ready neuronal nuclei can be obtained within one 
day. 
Background 
An increasing number of neurodevelopmental and neuropsychiatric disorders are 
thought to result from defective DNA:protein interactions specifically in neurons; 
furthermore, sustained changes in neuronal gene expression and behavior after 
exposure to certain drugs or stimuli are likely to involve chromatin remodeling, 
including DNA methylation and histone modification changes (Weaver et al., 
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2004b; Francke, 2006; Lubin and Sweatt, 2007; Nan et al., 2007; Tsankova et al., 
2007). However, even the most sensitive chromatin immunoprecipitation assays 
and most other approaches used to study the regulation of DNA and histone 
modifications, transcription factor binding etc., lack single cell resolution and 
instead require the preparation of homogenates from at least 103 - 107 nuclei. 
Consequently, detailed chromatin analysis was until now not feasible for nuclei of 
terminally differentiated neurons that typically reside in brain parenchyma 
intermingled with various types of glia and other cells mostly in a 2:1 – 1:2 ratio, 
dependent on species and brain regions (Herculano-Houzel et al., 2006; 
Sherwood et al., 2006).  
Recently, immunostaining in conjunction with fluorescence-activated cell sorting 
(FACS) was used successfully to selectively collect neuronal nuclei from human 
(postmortem) brain tissue for the purposes of retrospective birth dating (Spalding 
et al., 2005) or assessment of age-related changes in DNA cytosine methylation 
(Siegmund et al., 2007). However, these studies utilized the nuclear harvest for 
highly sensitive radiation and PCR assays, and it remained unclear whether the 
protocol could be modified for the purposes of chromatin immunoprecipitation 
and other techniques that require comparatively larger amount of input (for 
example, 105 107 nuclei). We provide a detailed protocol for selective sorting of 
neuronal nuclei from mouse and human brain in quantities sufficient for 
immunoprecipitation with different chromatin preparations (enzyme-based 
digestion and crosslinking/sonication), followed by microarray or PCR studies. In 
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addition, we introduce a transgenic mouse line for neuron-specific expression of 
GFP (enhanced green fluorescent protein)-tagged histone H2B. Evidence is 
presented that even under baseline conditions, promoter-bound histone 
methylation in neuronal samples is significantly different when compared to 
unsorted, or non-neuronal nuclei from the same brain region. Therefore, the 
methods presented here will be important for the study of molecular mechanisms 
governing epigenetic control of neuronal gene expression and chromatin 
remodeling specifically in mature brain. 
Results 
H2B-GFP transgenic mice  
The promoter of the subunit of the Ca2+/calmodulin dependent protein kinase II 
gene (CAMKII) was used to drive H2B-EGFP expression; as expected, this 
transgene labeled most of the neuronal populations in the fore- and midbrain, 
including cortex, striatum, hippocampus, with the notable exception of the 
GABAergic interneurons in cerebral cortex and hippocampus (Fig. 3-3). In 
contrast, labeling in hindbrain, including cerebellum, was less consistent (data 
not shown). The transgene-derived labeling of neuronal nuclei with H2B-EGFP 
was robust pre- and post-FACS (Fig. 3-2, panel a-d). To date, our oldest 
transgenic mice are 5 months of age and so far we did not observe any overt 
neurological phenotypes, even in animals expressing the fusion protein at 
comparatively high levels in CNS neurons. Likewise, no adverse effects were 
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reported for transgenic mice expressing high levels of H2B-EGFP in a wide 
range of tissues, including brain (Hadjantonakis and Papaioannou, 2004). 
Loss of nuclei during the procedure 
Each of the major steps in this protocol – (1) extraction of nuclei from the tissue, 
(2) ultracentrifugation, (3) immunolabeling and (4) fluorescence-activated sorting 
– could result in loss of nuclei, together totaling perhaps up to 50% of the 
neuronal nuclei in the starting material. However, despite of these limitations, the 
alternative approach, such as nuclei harvesting from primary neuronal culture, is 
likely not to improve results in a higher yield and would have the additional 
disadvantage of any ex vivo preparation.  
Nucleosomes are preserved in sorted nuclei 
Nucleosomes as the elementary unit of chromatin - are comprised of 146 bp of 
genomic DNA wrapped around core histones H2A, H2B, H3 and H4. To find out 
whether nucleosomal structures remain intact in sorted NeuN+ nuclei, we 
compared nucleosome occupancy at promoters in forebrain from unsorted and 
NeuN+ nuclei, using a modification-independent anti-H3 C-terminus antibody for 
ChIP-DSL in conjunction with M8K promoter array (Fig 3-4A,B). No significant 
differences between chip-to-input ratios of sorted NeuN+ and unsorted nuclei 
were observed. Instead, H3 occupancy at specific promoter sequences showed a 
strong correlation between the NeuN+ and unsorted samples (Spearman rank, r 
= 0.651370, p < 2.2e-16) (Fig. 3-4B). We conclude that promoter-bound 
nucleosomes are intact after the sorting procedure.  
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Differential histone H3 methylation in neuronal nuclei 
To find out whether or not neuronal chromatin, under baseline conditions, shows 
a histone methylation signature that is different compared to unsorted nuclei, we 
conducted ChIP for two histone lysine methylation marks, H3K4me2 and 
H3K9me3. All studies were conducted on the forebrain of male mice 8-12 weeks 
of age. Histone methylation levels were at 3 out of 4 - arbitrarily chosen - gene 
promoters significantly different in neuronal chromatin (Fig. 3-4C). Furthermore, 
in 2 out of 4 promoters (B2m, Mecp2), changes in the “open” mark, H3K4me2 
and the “repressive” mark, H3K9me3, were in the opposite direction (Fig. 3-4C).  
Notably, H3K9me3 levels at the Mecp2 promoter  - i.e., the Rett syndrome gene 
which is robustly and ubiquitously expressed in mature CNS neurons (Akbarian 
et al., 2001; Chen et al., 2001; Shahbazian et al., 2002b; Jung et al., 2003; Kishi 
and Macklis, 2004) - were higher in neuronal vs. unsorted chromatin. This 
particular finding was unexpected and requires further investigations.  
Next, we wanted to (i) find out whether the above findings can be extrapolated to 
species other than mouse and (ii) further confirm that histone lysine methylation 
at select gene loci is differentially regulated in neurons as compared to non-
neuronal cells residing in the same tissue. To this end, we utilized postmortem 
tissue from the human prefrontal cortex for ChIP with H3-tri-methyl-lysine 4 
(H3K4me3), a chromatin mark enriched at sites of active gene expression (Sims 
et al., 2003; Mikkelsen et al., 2007). For each tissue sample, NeuN 
immunopositive and immunonegative nuclei were sorted separately by FACS, 
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and then processed in parallel for anti-H3K4me3 ChIP followed by qPCR for the 
following genes: (1) The subunit 2B of the NMDA receptor (GRIN2B) and (2) 
brain-derived neurotrophic factor (BDNF); both these genes are in postnatal and 
adult brain predominantly or exclusively expressed in neurons (Huntley et al., 
1992; Sasner and Buonanno, 1996). (3) β-2 microglobulin (B2M), which in CNS 
is expressed in a mixed population of neuronal and non-neuronal cells and 
considered as a “housekeeping gene” in postmortem studies (Mimmack et al., 
2004; Lipska et al., 2006), and (4) the locus control region of the β-globin locus 
(HBB), which is highly regulated in erythopoetic tissues but silent and inactive in 
brain (Forsberg et al., 2000; Stadler et al., 2005). Levels of H3K4me3 at 
promoters of the neuron-specific genes, GRIN2B and BDNF, were consistently 
higher in chromatin of the NeuN+ nuclei as compared to NeuN- (Fig. 3-5). These 
changes were highly specific because H3K4me3 levels in chromatin surrounding 
B2M were higher in NeuN- nuclei, and furthermore, H3K4me3 at the HBB locus 
control region were overall very low (Fig. 3-5). Taken together, our findings in 
mouse forebrain and human prefrontal cortex suggest that - even at baseline - 
important differences exist between histone methylation signatures of neuronal 
and non-neuronal chromatin.   
Conclusions 
The protocol presented here should be particularly useful to investigators who 
wish to study chromatin regulation, including epigenetic mechanisms of neuronal 
gene expression, in the mature and the aging brain. The alternative approach, i.e. 
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the study of primary neuronal cultures or neuron-like cell lines, certainly is suited 
to model developmental mechanisms and neurodevelopmental disease (Chen et 
al., 2003; Ballas et al., 2005; Ge et al., 2006; Iwase et al., 2007; Yasui et al., 
2007; Nelson et al., 2008). However, neurons and other CNS cells are 
sustainable in culture, at best, for a few weeks (Yang et al., 2005; Gingras et al., 
2007) and therefore are not ideal from the viewpoint of chronic neuropsychiatric 
diseases, which often involve a protracted course, late onset and predilection for 
a specific neuronal subtype. Furthermore, the complexities of brain connectivity 
and circuitry, among a myriad of other factors, is difficult or impossible to model 
ex vivo. For example, in vivo treatment with antipsychotic drugs induces 
chromatin remodeling in cerebral cortex and striatum, an effect that cannot be 
mimicked in cortical or striatal cell cultures lacking input from monoamine 
pathways (Li et al., 2004; Huang and Akbarian, 2007; Huang et al., 2007).   
Finally, chromatin assays in whole brain tissue are potentially confounded by 
cellular heterogeneity, including potential shifts in cellular composition during the 
course of aging or due to disease. Given that chromatin immunoprecipitation with 
genome-wide coverage from as little as 10,000 cells is now feasible (Acevedo et 
al., 2007), it should be possible to use transgenic mice – including the CAMIIK-
H2B-GFP lines presented here – to selectively study the epigenome for highly 
defined subpopulations of neurons in the mouse. Furthermore, the relative 
resilience of nuclei in frozen-then-thawed postmortem brain tissue makes it 
possible to apply the techniques presented here to species other than small 
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laboratory animals, including normal and diseased human brain. It remains to be 
determined whether or not the approach presented here is applicable to tissues 
other than brain. When compared to sorting protocols that are based on 
trypsinization of tissue and sorting of intact (neuronal or non-neuronal) somata 
(Lobo et al., 2006), our approach has several advantages. First, it is applicable to 
frozen tissues. Second, the yield of recovered nuclei appears to be much higher, 
albeit direct comparisons are lacking. Third, it is comparatively simple as 
compared to related protocols. 
To summarize, the perspective to develop chromatin assays for specific types of 
neuronal populations of the mature brain, as described here, will be relevant for a 
wide range of physiological and neurological conditions related to transcriptional 
regulation and chromatin remodeling. 
Materials and Methods 
An overview of the procedure is provided in Fig. 3-1.  
Human. Procedures involving human postmortem brain were approved by the 
institutional review boards of the University of Massachusetts Medical School. 
Frozen tissues (prefrontal cortex) from 3 specimens (age range: 8-69 years, 
autolysis interval 5-28 hours) were obtained from the Brain and Tissue Banks for 
Developmental Disorders, University of Maryland (National Institute of Child 
Health and Human Development Contract NO1-HD-8-3284) and from a  brain 
bank at the University of California at Davis (Center for Neuroscience, Director Dr. 
Edward G. Jones).  
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Mice. A cassette, comprised of 8 kB of the CamIIK (α subunit) promoter and 1.4 
kB of histone H2b-eGFP cDNA (CaMK II-H2B-EGFP), was used to generate 3 
lines of transgenic mice by pronuclear injection. All the experiments were 
performed in strict accordance with Institutional Guidelines regarding use of 
experimental animals.  
Reagents and reagent setup 
Chemicals used include the following: 1 x PBS (Cellgro, 21-040-CV), Triton X-
100 (Fluka, 93426), Igepal CA-630 (NP-40) (Sigma, 1-3021), Protease inhibitor 
cocktail tablets (Roche, 11697498001), Phenylmethanesulfonyl Fluoride (PMSF) 
(Sigma, P7626), Mouse anti-NeuN (Upstate, MAB377), Goat anti-mouse IgG, 
Alexa Fluor 488 (Invitrogen, A11029), Bovine serum Albumin (BSA) (Sigma, B-
4287), Normal goat serum (Vector, S-1000), Micrococcal nuclease (Sigma, N-
3765), Protein G Agarose, (Upstate, 16-266), Rabbit Anti-H3 (Abcam, ab1791), 
Rabbit Anti-H3K4me2 (Upstate, 07-030), Rabbit Anti-H3K9me3 (Upstate, 07-
442), Rabbit Anti-H3K4me3 (Upstate, 07-473), Normal rabbit IgG (Upstate, 
120370) 
Nuclei Extraction Buffer (NEB): 0.32 M Sucrose, 5 mM CaCl2, 3 mM Mg(Ac)2, 0.1 
mM EDTA, 10mM Tris-HCl (pH8), 1 X Protease inhibitor cocktail, 0.1 mM PMSF,  
w/o 0.1% Triton X-100, w/o 0.1% NP-40. Sucrose Cushion: 1.8 M Sucrose, 3 mM 
Mg(Ac)2, 10 mM Tris-HCl (pH8). Blocking Solution: 0.5% Bovine serum albumin 
(BSA), 10% normal goat serum, in 1 x PBS. 
Nuclei extraction from brain tissue 
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Total nuclei were extracted via sucrose gradient ultracentrifugation. In the work 
presented here (mouse), each sample was derived from a single forebrain (adult 
males, 8-12 weeks of age); (human) 1000 mg of cerebral cortex. All the reagents 
used were pre-chilled and the entire procedure was performed on ice. Fresh or 
frozen samples were homogenized by douncing 50 times in 5 mL NEB with 0.1 
% Triton X-100, or alternatively, 0.1 % NP-40. Triton X-100 was preferable if 
nuclei require immunotagging (with NeuN, for example), while NP-40 as a milder 
detergent left more nuclei intact and sufficient when working with nuclei 
expressing GFP. After douncing, brain homogenates were transferred into 14 mL 
ultracentrifuge tubes (Beckman, 14 x 95 mm, 344061), and 9 mL of Sucrose 
Cushion was carefully loaded directly to the bottom of the ultracentrifuge tube. 
Ultracentrifugation was performed at 24400 rpm for 2.5 hrs at 4 °C (Beckman, 
L8-70M, SW28 rotor). After centrifugation, a nuclei pellet - thin and typically with 
a light yellow taint - was formed on the bottom of the tube. The sticky white tissue 
debris was restrained in the middle interface of the two sucrose layers. 
Supernatant, including debris, was carefully removed. 1200 μl of chilled 1 x PBS 
was then added into the tube and incubated without disturbing the pellet, for 20 
min on ice. This incubation is recommended because the nuclei pellet is easier to 
dissociate and consequently, there will be less damage to the nuclei. After 
incubation, the nuclei were dissociated by pipetting up and down. FACS required 
single nuclei in solution but excess pipetting tended to break nuclei, at least in 
the unfixed preparations. Pipetting required optimization by checking the nuclei 
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“quality” (intact single nuclei, non-adhering, without debris) under the light 
microscope. The total number of nuclei was counted by using a hemacytometer. 
One mouse forebrain typically yielded 20-30 x 106 unfixed nuclei after 
ultracentrifugation.  
One alternative option was to fix the nuclei by directly douncing the tissue in NEB 
containing 1% formalin. Typically, we fixed with formalin at room temperature for 
5-10 min, and then added glycine to a final concentration of 125 mM. The fixed 
nuclei were pelleted by centrifugation, re-suspended in 5 mL of NEB, and 
subjected to ultracentrifugation as described above. Nuclei clumping during 
isolation was – in our experience – usually to blame if the final yield was lower 
than expected. For unfixed samples, factors that appear to promote clumping are 
(i) contamination from brain debris, or (ii) DNA leaking from broken nuclei, which 
appears to be alleviated via careful handling and performing the whole procedure 
on ice. When a fixation step was included (see above), the only way to 
significantly alleviate the clumping was to remove Ca2+ from the NEB, albeit this 
increased the proportion of broken and damaged nuclei. Thus, lower post-FACS 
yield is to be expected when working with fixed samples.  
Immunotagging of neuronal nuclei  
Next, neuronal nuclei were tagged by immnofluorescence staining, using an anti-
NeuN antibody (Fig. 3-2A, panels e-j).  Firstly, anti-NeuN (Ms) and anti-Ms IgG 
(Alexa 488) antibodies were co-incubated at room temperature for 5 min (Table 
3-1), then nuclei solution was added and the mixture incubated in darkness for at 
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least 20 min at 4 °C before FACS. The proportion of NeuN positive nuclei in the 
material recovered after ultracentrifugation was about 50 %. The FACS 
background signal was minimal in these preparations (Fig. 3-2B, panel a). 
Neuronal nuclei isolation via FACS 
Next, the fluorescent nuclei (H2B-GFP transgene or NeuN labeled) were filtered 
through a 40 µm Nitex mesh to remove any remaining clumps, and then run 
through a FACS machine (Vantage SE/Diva, BD Biosciences) with proper gates 
settings based on the size and density of nuclei, to ensure that only single 
NeuN+ nuclei were sorted, which typically included 40 % of the whole population 
(Fig. 3-2B, panel b). After FACS, the NeuN+ nuclei were reanalyzed to confirm 
the purity. Sample purity typically is > 95%. For selected samples, the purity of 
NeuN+ nuclei was checked under the microscope (Fig. 3-2A, panel c, d and g, 
h). FACS sorting should be performed on the same day as extraction and NeuN 
labeling of nuclei. For a subset of experiments, including those involving human 
postmortem brain, immunonegative (NeuN-) nuclei were collected and processed 
in parallel to the fraction of neuronal (NeuN+) nuclei. 
Expected yield of neuronal nuclei 
We usually obtained – from a single mouse forebrain – 2.5 x 106 NeuN+ nuclei 
post-FACS if fixative was added to the NEB and up to 8 x 106 nuclei if processed 
unfixed. We usually obtained from 1000 mg of human (prefrontal) cerebral cortex 
5 x 106 NeuN+ nuclei if processed unfixed. 
Post-FACS nuclei pelleting  
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After FACS, nuclei were collected in a large volume of 1 x PBS, roughly 4 x 106 
nuclei in 10 mL of 1 x PBS. This was not ideal for ChIP because processing such 
a large volume is associated with very high expense and potential “wasting” of 
antibodies and other reagents. Therefore, pelleting was important, but the 
challenge thereby was that post-FACS nuclei became fragile and most of them 
were destroyed by centrifugation in 1 x PBS. Therefore, we tested different 
buffers and noticed that the presence of Ca2+ and Mg2+ is crucial for integrity of 
nuclei during pelleting. Hence, the concentration of sucrose, Ca2+, and Mg2+ in 
post-FACS nuclei solution was adjusted by adding the following to each 10 mL of 
post-FACS nuclei: 2 mL of 1.8 M Sucrose, 50 μl of 1M CaCl2, and 30 μl of 1M 
Mg(Ac)2. Samples were mixed gently, incubated on ice for 15 min, and 
centrifuged at 3000 rpm for 15 min at 4 °C.  
Chromatin immunoprecipitation 
The FACS sorted nuclei were prepared either by micrococcal nuclease digestion 
for native chromatin immunoprecipitation (NChIP) as described (Huang et al., 
2006), or in case of fixed nuclei, sheared by sonication (Branson Sonifier 250) for 
XChIP. (Typically, samples were sonicated at power level 6 (Branson, Danbury 
CT) in ice water, by applying 10 runs of 30 sec impulse with 1 min resting interval. 
Again, sonication conditions need to be optimized before each experiment.) In 
the work presented here, only NChIP was used. In brief, micrococcal nuclease 
(MNase) digestion was performed with a working concentration of 4U/mL at 37 
°C for 5 min.  The resulting mono-nucleosomal preparation (around 146 bp) (See 
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Supplementary Figure 3-1A) was precleaned by incubating with protein G 
agarose (which should also remove the antibodies used for NeuN labeling of 
nuclei) and then subjected to immunoprecipitation using antihistone antibodies 
(see Reagents). Control experiments included samples processed with normal 
rabbit IgG, in parallel to samples with specific antibodies. Typically, we used 0.5 
– 8 x106 nuclei as input.  
Real time PCR 
Quantification of DNA extracted from immunoprecipitates was done by real time 
PCR using custom-designed primers targeting the promoter regions of the 
following genes: (mouse) methyl CpG binding protein 2 (Mecp2), glutamate 
decarboxylase 1 (Gad 1), 2　 -microglobulin (B2m), and Glial fibrillary acidic 
protein (Gfap); (human) glutamate receptor, ionotropic, N-methyl D-aspartate 2B 
(GRIN2B), brain derived neurotrophic factor (BDNF), 2　 -microglobulin (B2M), 
and the locus control region of the globin genes (HBB). Mouse Mecp2 primer 
sequence (119 bp): forward GCCTCTTTTCCCTGCCTAAA, reverse 
CCCTTGCTCTTTGTCGAGAT; Gad 1 (98 bp): forward 
TGTCTCACCAAAGTCCCTGTC, reverse CACGTCTGGTTCGGTGTCT; B2m 
(112 bp): forward GGGAAAGTCCCTTTGTAACCT, reverse 
GCGCGCGCTCTTATATAGTT; Gfap (100 bp): forward 
TACCAGAAAGGGGGTTCCTT, reverse AACTCCTCTCACCCCACTGA. Human 
GRIN2B primer sequence (64): forward TCCTCTTCCATTCAGGTTGG, reverse 
GGCTATACCATTCCTGGGACA; BDNF (102): forward 
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AGCCCAACAACTTTCCCTTT, reverse GAGAGCTCGGCTTACACAGG; B2M 
(99): forward GGGCACCATTAGCAAGTCAC, reverse 
GGCGCTCATTCTAGGACTTC; HBB (87): forward CCCCAGGTAGTTCCCTTT 
reverse TTCAAGGCCCTGTAGTTGCT. Quantification was done as described 
(Huang et al., 2006). For each of the antibodies used in this study (anti-H3K4me2, 
-H3K9me3, and –H3K4me3), specific signal was limited to input and chip 
fractions, and differed from controls by at least 3-4 cycle thresholds (See 
Supplementary Fig 3-1B,C). 
ChIP-on-Chip 
To study histone occupancy at gene promoters on a larger scale, a mouse 
promoter array, M8K (Aviva Systems Biology, San Diego, CA), containing 8000 
40-mer oligonucleotide probes targeting gene promoters, was used. The DNA 
samples were amplified and labeled by Aviva’s ChIP-GLAS system. Briefly, both 
input and immunoprecipated (ChIP) DNA were biotinylated and annealed to the 
M8K-Oligo-Mix. The DNA samples were then amplified by ligation mediated PCR 
with T3 and T7 based primers (25 cycles), labeled with Atto 550 or 647, and 
hybridized onto the chip. Amplification, labeling, hybridization, and washing was 
carried out according to the manufacturer’s instruction (Aviva, AK-0524). Slides 
were scanned with DNA Microarray ScannerBA (Agilent Technologies, Santa 
Clara, CA, USA) and intensities extracted with Feature Extraction Software 
Version 9.1 (Agilent Technologies, Santa Clara, CA, USA). Raw data were read 
into the R statistical computation environment for preprocessing and data 
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analysis (R: Development core team (2004). R: A language end environment for 
statistical computing. Vienna, Austria. http://www.r-project.org). Local 
background intensities were subtracted from raw signals and negative values 
were replaced with small positive ones. Signals were then normalized using a 
variance stabilization method described in (Huber et al., 2002; Gibbons et al., 
2005) and implemented in the vsn Bioconductor package (Gentleman, RC. et. al., 
Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biology 5, R80 (2004)).  
Other amplification procedures 
We used the Genomeplex whole genomic amplification kit (WGA2, Sigma) to 
amplify DNA immunoprecipitates, which resulted in 2 to 5 ug of (amplified) DNA 
from starting material (10 ng of input DNA;  ChIP DNA from 0.5x106 nuclei).  
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Figure 3-1. Outline of the procedure to isolate neuronal nuclei from brain 
for chromatin immunoprecipitation. 
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Figure 3-2. Neuronal nuclei isolated from adult brain via FACS.  (A) Digitized 
images of nuclei extracted from forebrain of adult (a-d) CAMIIK-H2B-GFP 
transgenic mice, and (e-j) wild type mice labeled with NeuN immunoreactivity, as 
indicated pre and post (FACS sorting), and after pelleting. Green channel for (a, 
c) GFP or (e, g, i) NeuN; blue channel for DAPI. Notice that post-FACS samples 
are comprised entirely of neuronal nuclei. Bar = 20 m.  (B) Representative 　
FACS scatter plots from (a) negative control (NC) processed without NeuN 





Figure 3-3. Neurons expressing H2B-GFP transgene. Digitized images from 
8 week old CAMIIK-H2B-GFP mice.  (a) Cerebral cortex. Notice GFP (green) 
nuclei across layers II-VI, but not in layer I or white matter (WM). (b) caudate-
putamen and (c) hippocampus. (d-f) Nuclei extracted from forebrain and 
processed for NeuN (red), and nucleophilic dye, DAPI (blue). Notice that GFP 
(green) expression is limited to 5 of the 6 NeuN immunoreactive nuclei. Arrows 
label GFP-, NeuN- nuclei, * labels GFP-, NeuN+ nucleus. (g) Section from 
cerebral cortex labeled with anti-GAD67 antibody (red). Notice absence of GFP 





Figure 3-4. Neuron-specific chromatin signatures in mouse brain. (A) 
Representative gel picture for 25 cycle PCR product (ChIP-GLAS) from 4 
independent replicates of Input I and ChIP C, and water control W. (B) Scatter 
plot showing correlation between Chip-to-input ratios signal from NeuN+ sorted 
nuclei (NeuN+ FACS) (x-axis) and unsorted nuclei (NON-FACS) (y-axis), using 
modification-independent antibody against C-terminus of histone H3 anti-H3. (C) 
Bar graphs showing ChIP-to-input ratio (y-axis) for (top row) dimethylated H3-
lysine 4 (H3K4me2) and (bottom row) trimethylated H3-lysine 9 (H3K9me3) as 
determined for Mecp2, Gad1, B2m, and Gfap gene promoters in chromatin of 
NeuN+ FACS and NON-FACS nuclei from mouse forebrain. Data shown as 





Figure 3-5. Neuron-specific chromatin signatures in human prefrontal 
cortex. Bar graphs showing ChIP-to-input ratio (y-axis) for trimethylated H3-
lysine 4 (H3K4me3) at GRIN2B, BDNF and B2M promoters, and HBB (β-globin) 
locus control region in chromatin of NeuN positive (NeuN+) and negative (NeuN- ) 
FACS sorted nuclei from human prefrontal cortex. Data shown as mean ± S.E.M., 
N =3 specimens/sorting. The NeuN+ fraction showed, in comparison to NeuN- 
fraction of the same subject,  increased levels of H3K4me3 at GRIN2B and 




Table 3-1: Antibodies used for immunotagging of neuronal nuclei. 
 135
Supplementary Figure 3-1: Quality controls for native chromatin 
immunoprecipitation (nChIP) followed by quantitative real-time PCR. (A) 
Images from ethidium bromide-stained 1.3 % agarose gels showing chromatin 
DNA from mouse forebrain before (MNase-) and after (MNase+) micrococcal 
nuclease (MNase) digestion. All samples were treated with RNase A. The DNA 
ladder is shown on the left side of gel picture. Notice approximately 146 bp DNA 
fragment only in MNase+ samples. (B), SYBR-green based melting curves from 
immunoprecipitates with anti-H3K4me2 antibody using primer pairs for mouse 
B2m and Gad1; notice single peak for specific product. (C) Representative 
amplification curves of inputs (black circles), immunoprecipitates (red circles) and 
IgG control (green circles), dotted line indicating cycle threshold. Data shown for 
Gad1 and B2m separately. Notice samples processed with non-specific IgG 




CHAPTER V: GENERAL DISCUSSION 
In this dissertation, I investigated the roles of Setdb1, a histone H3K9 specific 
methyltransferase, in adult mouse brain. I firstly showed a downregulation profile 
of Setdb1 expression during normal mouse brain development, which was also 
replicated in postmortem human brain samples from embryo to adulthood 
(unpublished data). I then generated genetically engineered mice in which a myc-
tagged full-length Setdb1 was over-expressed in mature central nerve system 
neurons. By using these transgenic tools, I identified a number of Setdb1 target 
genes with an unexpected preference towards ionotropic glutamate receptor 
genes. Setdb1-mediated repressive chromatin formation was detected in the 
NMDA receptor 2B subunit Grin2b gene locus, which was correlated to a 
decrease of both Grin2b expression and function in hippocampus. Blockage of 
Grin2b activity was shown to improve depression in both preclinical and clinical 
studies (Maeng et al., 2008; Preskorn et al., 2008). Intriguingly, we also observed 
a specific antidepressant-like phenotype in the Setdb1-overexpressing mice, in 
the context of normal or even improved cognitive functions. However, when 
introduced to diseased brains with genetic ablation of Mecp2 - the primary 
disease gene for Rtt syndrome (RTT), the overexpression of Setdb1 did not 
ameliorate the behavioral deficits; on the contrary, it even accelerated the 
premature death of the RTT mice. 
Setdb1 is well-studied as a transcriptional repressor in regulating euchromatic 
gene expression, however, its preferential in vivo target - trimethylation of H3K9 
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(H3K9me3) is primarily accumulated in constitutive heterochromatin regions. In 
the mammalian system, the HMTs Suv39h1 and 2 are thought to primarily 
establish H3K9me3 in heterochromatin regions, but this leaves the role of Setdb1 
unclear. Does Setdb1-mediated H3K9me3 also contribute to higher-order 
chromosome organization? My work did observe a significant increase of 
H3K9me3 in major satellite DNA repeats after artificial up-regulation of Setdb1 in 
adult brains. Setdb1-mediated hyper-trimethylation of H3K9 and the 
condensation of pericentromeric heterochromatin structure were also observed in 
diseased brains from animal models of neurodegenerative diseases (Ryu et al., 
2006; Lee et al., 2008). This evidence suggests that besides its euchromatic 
functions, Setdb1 still has the potential to impact constitutive heterochromatin 
organization under aberrant circumstances in adult brain. Studies from 
Drosophila dSetdb1 also suggested Setdb1-associated heterochromatic 
functions. dSetdb1 was shown to be essential for the establishment of H3K9me3 
in DAPI-condense pericentric heterochromatin in germ-line stem cells, but such 
role was taken over by Su(var)3-9 in later developed egg chamber cells (Yoon et 
al., 2008). In light of this, one can speculate that mammalian Setdb1 is also in 
charge of heterochromatic H3K9me3 formation during very early development. 
Indeed, it has been shown that Setdb1-null mice died during peri-implantation 
between 3.5 to 5.5 dpc (Dodge et al., 2004), while Suv39h1 and Suv39h2 
double-null fetuses developed normally until day E12.5 (Peters et al., 2001). My 
in situ hybridization data on fetal brains also showed the most robust signal of 
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Setdb1 mRNA in the germinal neuroepithelium. Taken together, it will be 
interesting to look into the genomic localizations and functions of Setdb1 in early 
developing brain, especially in the neural precursor cells. 
As showed in current studies, Setdb1 is downregulated during mouse brain 
development. Since Setdb1-null mouse is lethal, alternatively, we interfered with 
the normal expression profile by maintaining a high level of Setdb1 in developed 
brains. Surprisingly, instead of detrimental effects on brains functions, an 
improved mood function represent as antidepressant-like behavioral changes 
were observed in two transgenic lines of Setdb1 mice. Global neurological 
functions, as well as other higher brain functions such as cognition, anxiety and 
stimulant drug responses, were generally normal in Setdb1 mice, which indicated 
that Setdb1 may specifically affect genes involved in mood regulating circuit of 
depression. Indeed, by using a genome-scale microarray screen, we indentified a 
very limited Setdb1 target gene profile (32 gene hits out of around 4000 genes on 
chromosome 6, 8, 16) with a high specificity toward ionotropic glutamate receptor 
genes. Setdb1-mediated transcriptional repression was further verified on the 
NMDAR 2B subunit Grin2b gene, which is the new target in therapy for major 
depression. It has been reported that sustained antidepressant effects were 
elicited by the administrations of Grin2b-selective NMDAR antagonists in both 
preclinical animal models and clinical trials (Maeng et al., 2008; Preskorn et al., 
2008). Mice with conditional knockout of Grin2b in hippocampus showed lower 
levels of anxiety in light-dark box and modified elevated plus maze tests (von 
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Engelhardt et al., 2008). Moreover, single nuclei polymorphisms (SNPs) screen 
and linkage scan indicated a strong association between human GRIN2B gene 
and bipolar disorders (Fallin et al., 2005; Avramopoulos et al., 2007). Therefore, 
the downregulation of Grin2b gene expression in Setdb1 overexpression mice is 
very likely to be the main cause of their antidepressant-like phenotype. My 
findings provided for the first time a direct genetic evidence for the involvement of 
Grin2b gene in depression. To provide further evidence indicating the direct 
relationship between Setdb1-related molecular changes and the antidepressant-
like phenotype, future work may include brain region-specific (for example, 
hippocampus) alteration of Setdb1 expression (overexpression or knock-down) 
through in vivo virus transduction or conditional genetic engineering strategy. 
The Setdb1-targeting site on mouse Grin2b locus was mapped to a 5’-
untranslated region in intron III, which is located distant (around 31.5 Kb 
downstream) from the transcriptional starting site (TSS). This raises the question, 
how does this distal Setdb1-binding fragment affect Grin2b gene transcription? 
By performing Chromosome Conformation Capture (3C), we identified a higher-
order chromatin loop structure on Grin2b locus, which tethers the Setdb1-
targeting site to another intronic sequence relatively proximate to TSS (~12 Kb 
downstream of TSS). We found that this “~12 Kb” intronic sequence is enriched 
for the binding of KAP1, a well-studied Setdb1-associating transcriptional 
corepressor. Such Setdb1/KAP1-mediated loop formation may repress Grin2b 
gene expression by interfering with transcriptional initiation or elongation; 
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therefore, it will be interesting to check whether the levels of certain transcription-
related epigenetic marks, for example, H3K4me3, H3K9me2, H3K36me3, and 
H3K79me2, are affected at defined genomic loci by the increase of Setdb1. 
Moreover, a strategy of introducing deletion or site mutations to the Setdb1-
targeting site on Grin2b locus will provide direct evidence for the involvement of 
Setdb1 in the Grin2b loop formation and transcriptional repression. Also, since no 
evidence indicating direct DNA binding properties of either Setdb1 or KAP1, 
further studies are needed to identify the DNA-binding components of this loop 
formation. KRAB-zinc finger proteins (KRAB-afp) transcription factors are the 
most likely candidates, since potential KRAB binding fragments were indentified 
in both Setdb1 and KAP1 interacting sequences on Grin2b loci across different 
species (mouse, rat and human). However, KRAB-zfp proteins are a superfamily 
of hundreds of different transcription factors with sequence-specific DNA binding 
domains; it will be a challenge to indentify distinct KRAB-zfp proteins for Grin2b 
or any other Setdb1 target genes. The methyl-CpG binding protein 1 (MBD1) 
could be another potential candidate. Grin2b promoter region contains a CpG 
island, which can be subjected to methylation to repress gene expression. MBD1 
may bind to the methylated promoter region and recruit Setdb1 to maintain the 
repressive loop formation. Moreover, MBD1 may facilitate the HMT activity of 
Setdb1 by recruiting mAM (also known as MBD1-containing chromatin-
associated factor, MCAF) (Fujita et al., 2003; Wang et al., 2003). Interestingly, 
almost all the Setdb1 target genes we identified (28 out of 32) are over the 
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average size (>=20 Kb, with the maximum over 1500 Kb), and the majority of 
targeting sites (23 out of 32) are located in the non-coding regions distant from 
TSS (>=10 Kb). This may suggest that the formation of a chromatin loop 
structure is a common mechanism underlying Setdb1-mediated transcriptional 
repression. 
Current knowledge of epigenetic mechanisms underlying brain functions is 
mainly focused on the “open” chromatin mark – histone acetylation, and can be 
simplified as a model: “more acetylation = gene activation = good brain functions”. 
However, the heritable epigenetic changes usually require stable and long-term 
alterations in gene expression, which is beyond the regulating ability of histone 
acetylation. Therefore, although initiated by histone acetylation, there must be 
some subsequent nuclear events to stabilize and maintain the changes of gene 
transcription status. In this study, we showed that Setdb1-mediated elevation of 
histone H3K9 methylation was related to improved brain functions with 
decreased levels of depression and enhanced long-term memory. Intriguingly, 
Jakobsson and his colleagues reported that mice with genetic ablation of KAP1 
exhibited increased level of mood disturbances, as indicated by enhanced 
anxiety-like behavior and increased sensitivity to stress (Alter and Hen, 2008; 
Jakobsson et al., 2008). In the same study, decreased H3K9 methylation was 
shown to be involved in the regulation of defined gene expression, which may 
contribute to the anxiety-related behavior changes (Jakobsson et al., 2008). 
Contradictory evidence showing destructive roles of Setdb1-mediated H3K9 
 143
methylation in brain functions were also reported in the animal models of 
neurodegenerative diseases (Ryu et al., 2006; Lee et al., 2008). The increase of 
Setdb1 expression and H3K9 hyper-methylation was observed in brains from 
transgenic R6/2 HD mice and Huntington’s diseases (HD) patients, as well as the 
mutant mice with monoallelic deletion of CREB binding protein (CBP), and were 
considered as the direct cause of striatal neuronal atrophy that underlies the 
pathophysiology of both brain diseases (Ryu et al., 2006; Lee et al., 2008). 
However, no evidence of striatal neuronal death or obvious behavioral deficits 
(via locomotor activity, motor coordination, life span) were observed from our 
transgenic mice with over-expression of Setdb1 in forebrain mature neurons. On 
the contrary, considering the improved mood and cognitive functions in our 
Setdb1 mice, it is possible that the increased Setdb1 expression observed in 
diseased brains could be a self-compensatory process involved in counteracting 
the neurodegenerative dysfunctions. Nevertheless, all these studies extend the 
current “acetylation model” by introducing a relatively more stable epigenetic 
mechanism - the “closed” chromatin mark H3K9 methylation – into brain disease 
research. 
Several lines of evidence suggest that there might be functional redundancy 
between Setdb1 and the methyl-CpG binding protein 2 (Mecp2), since both 
proteins are involved in transcriptional repression and heterochromatin formation 
by employing similar epigenetic mechanisms, such as histone deacetylation, 
histone H3K9 methylation, and DNA methylation. However, once introduced to 
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Mecp2-null brains, the overexpression of Setdb1 did not ameliorate the brain 
deficits. Although this finding seems to disapprove my original hypothesis, it 
remains possible that increased expression of Setdb1 already exists in the 
Mecp2-null brains, which could be the same compensatory mechanism as the 
elevated Setdb1 expression observed in the HD and CBP-mutant brains (Ryu et 
al., 2006; Lee et al., 2008). Additionally, this may also be the reason why 
H3K9me3 levels remained intact in the pericentric heterochromatin region in 
Mecp2-null neurons. Therefore, it will be interesting to look at the expression, 
function, and even sub-nuclear localization of Setdb1 in Mecp2-null neurons. 
However, even if such a mechanism of Setdb1 compensation does exist in 
Mecp2-null brain, obviously it is not powerful enough to reverse or stop the brain 
deteriorations. Since Mecp2 plays multiple roles in the epigenetic control of 
normal brain functions, future studies to identify potential therapy for Rtt 
syndrome should include more than one regulating mechanism, in addition to 
consideration for other confounding factors like region specificity and gene 
dosage. 
The results from my dissertation work will lead to a better understanding of the 
functions of histone H3K9 methyltransferase Setdb1 in rodent brains, and may 
provide new targets for the therapeutic treatment of psychiatric disorders. 
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